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Antimicrobial resistance (AMR) occurs when micro-organisms (including bacteria, 
viruses, fungi and parasites) survive exposure to a medicine that would usually kill them 
or halt their growth. This is a natural phenomenon which is becoming much more 
common. AMR is a growing public health crisis both globally and in New Zealand. It 
limits our ability to effectively prevent and treat infectious diseases, and poses a threat to 
many practices and standards of modern medicine. The rapid development of bacterial 
resistance to antibiotics is particularly concerning. 
AMR is a highly complex issue. There are human, animal and environmental reservoirs 
of AMR, with complex transmission pathways between them. Their relative importance 
is unclear and contested. There is increasing recognition of AMR as a ‘One Health’ issue 
at the nexus of human, animal and environmental health. Coinciding with this is the 
recognition that addressing AMR will require new ways of thinking that transcend 
disciplinary boundaries: we need to think of AMR as a ‘system’ of interconnecting 
components, and seek to understand the problem as a whole, and not just its component 
parts. However, there are few examples of such approaches being applied in practice. 
This thesis describes an integrative approach to understanding AMR, which is 
underpinned by both One Health and EcoHealth principles. EcoHealth is a research 
paradigm based on the principles of systems thinking, transdisciplinary research, multi-
stakeholder participation, sustainability, gender and social equity, and translating 
knowledge into action. The chosen method, participatory system dynamics, was used to 
model stakeholder understandings of the causes and effects of AMR in New Zealand, 
with a particular focus on identifying feedback loops that drive system behaviour over 
time. Feedbacks are formed by variables connecting into loops that either reinforce or 
balance changes happening in the system. 
This research involved 27 interviews with 31 purposively selected stakeholders who have 
clinical, academic/research, policy, community and industry experience related to AMR.  
From the interviews, system dynamics modelling methods were used to build causal loop 





people believe the system works and to integrate the different parts of this complex 
problem in order to identify key leverage points for improving policy and practice.  
Many of the feedback loops arising from this research have not been previously identified 
in the literature. The results of this research suggest important connections between AMR 
and other broad issues including poverty, inequality, water quality and intensive farming 
practices. This is the first time that participatory system dynamics modelling has been 
used to integrate human, animal and environmental aspects of antimicrobial resistance. 
It is hoped that future work will refine and strengthen the model through workshops with 
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1.1 Outline of the problem 
Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi or parasites survive 
exposure to drugs that would usually be expected to have killed them. This phenomenon 
has been recognised since the early 1940s (1), and has grown into a global public health 
crisis that threatens our ability to effectively treat and prevent infectious diseases (2, 3). 
According to the World Health Organisation, “without harmonized and immediate action 
on a global scale, the world is heading towards a post-antibiotic era in which common 
infections could once again kill” (2 p.vii).  Infections with resistant organisms limit 
treatment choices (4) and may require treatment with less desirable antibiotics, which are 
often more toxic, more expensive and less effective (5). Resistant infections are 
associated with a higher risk of poor clinical outcomes including longer hospital stays, 
delayed recovery, disability in the long-term, and increased risk of mortality (6).  
There is increasing political recognition of AMR as a major public health issue and 
acknowledgment that controlling it is essential to long term economic development and 
global wellbeing (7). The threat of AMR to human health has been likened to that of 
climate change (8, 9); both are multifactorial, rapidly emerging issues with the potential 
to become self-sustaining and catastrophic (8). If the increasing trajectory of AMR is not 
halted, substantial increases in incurable infections are predicted (10, 11). Antibiotics are 
the most commonly used type of antimicrobial (12), and the general term ‘antimicrobial 
resistance’ is commonly used to refer to antibiotic resistance. In this thesis, antimicrobial 
resistance and antibiotic resistance will be used interchangeably.  
AMR is a highly complex issue. A wide range of risk factors have been described across 
human, animal and environmental systems, but their relative importance is unclear (7). 
Complexity arises from the fact that “use of an antimicrobial anywhere can increase 
resistance to any antimicrobial anywhere else” (13 p.78). That is, antibiotic use has 
implications far beyond the individual or sector using them (14). Antimicrobial drugs are 
widely used in human and veterinary medicine, and for agricultural purposes (1, 15-17). 
Although AMR is intrinsically a biological phenomenon, the conditions fostering its 





Increasingly, researchers and policymakers are realising the importance of understanding 
AMR as a complex network involving human, animal and environmental health (19), as 
part of a ‘One Health’ approach. A One Health approach recognises that human health is 
intrinsically related to the health of animals and the environment (7), and that 
multidisciplinary collaboration at a range of scales is necessary to tackle such problems 
(20).  
As well as a One Health approach, this research is underpinned by EcoHealth principles. 
Both research approaches incorporate holistic, systems-level conceptualisations of 
human health and its relationship with the health of animals and the environment, 
recognising the complexity of linkages between these three domains (21-24). The 
ecosystem approach to health addresses problems that bring together health, equity, and 
sustainability, using principles of systems thinking, transdisciplinary research, 
participation, sustainability, gender and social equity, and ‘knowledge-to-action’ (25).  
Calls for systems-based approaches to public health are becoming common (26), but so 
far have been under-used in public health (27, 28). Systems thinking is a way of looking 
at complex problems that seeks to understand the interconnections between elements of 
a system in order to achieve a certain purpose (e.g. to reduce AMR) (29). 
In order to deal with complexity, integrated approaches to health (such as One Health 
and EcoHealth) need to be iterative, adaptive and participatory, and participatory 
modelling provides a practical way for meeting these requirements (30). Participatory 
modelling purposefully brings affected stakeholders together to facilitate a process of 
knowledge sharing and model co-generation, to improve planning and decision making 
in a given context (30). Participatory modelling has been proposed as a useful tool for 
enabling One Health collaboration between stakeholders in practice (20). Further, it has 
been recommended for operationalising the principle of systems thinking that is common 
to both One Health and EcoHealth (30). Participatory modelling is transdisciplinary and 
facilitates knowledge sharing, knowledge generation, negotiation and planning (30), by 
allowing integration of various types of information (31). The process of model building 
helps stakeholders to clarify their own mental models of the problem, appreciate the 





1.2 Research questions and process 
Given the established complexity of AMR and the need for integrated approaches, this 
project aims to integrate the disparate elements of knowledge about AMR in New 
Zealand (from human, animal and environmental health dimensions) using One Health 
and EcoHealth principles. The specific research questions are: 
1. What are the relationships between different aspects of human, animal, and 
environmental health in relation to antimicrobial resistance, within the New 
Zealand cultural and political context, as perceived by a variety of stakeholders? 
  
2. What are the feedback loops that are driving trends in AMR over time in New 
Zealand? 
During this research I was guided by a supervisory team with diverse expertise. Alex 
Macmillan has expertise in EcoHealth approaches and participatory system dynamics 
modelling. Patricia Priest has expertise in One Health approaches, as well as on the topic 
of antimicrobial resistance and the stakeholders involved in AMR in New Zealand. Kate 
Morgaine has expertise in qualitative research approaches. Jeff Foote, a project advisor, 
also has expertise in systems approaches.  
1.3 Structure of this thesis 
The structure of the remainder of this thesis is outlined below. 
In Chapter Two, I provide further background about AMR and its public health 
significance. I provide detail about the human, animal and environmental aspects of the 
problem, and discuss the need for more integrative approaches to tackling AMR.  
Chapter Three comprises a literature review on qualitative and quantitative causal models 
of antimicrobial resistance. Very few models that incorporate human, animal and 






Chapter Four describes the underpinning methodological considerations for this research. 
I describe my personal research approach, One Health and EcoHealth research positions 
and principles, and introduce systems thinking in more detail. System dynamics is then 
explained more specifically, and ultimately participatory system dynamics is justified as 
the research method.  
Chapter Five describes the methods used to build a qualitative system dynamics model 
(causal loop diagram, CLD) of AMR in New Zealand. It details how to read these 
diagrams, outlines the process of interviewee selection and recruitment, and describes 
the interviews and the data analysis process (thematic analysis and development of the 
causal loop diagrams). 
In Chapter Six, the first results chapter, I outline the characteristics of the included 
participants and describe the results of the thematic analysis of interviews. 
Chapter Seven, the second results chapter, describes the causal loop diagrams developed 
in the study and combines them into an overall model. 
In Chapter Eight, the final chapter, I discuss the wider meaning of the results, what this 
study adds to the literature about AMR, evaluate the study and discuss implications for 








This chapter begins by providing background information about what antimicrobial 
resistance (AMR) is, how it develops, and its public health significance globally and in 
New Zealand. The complexity of the problem is illustrated through separate 
consideration of its human, animal and environmental dimensions. Finally, there is 
discussion of the importance of a more integrative approach to support understanding 
and decision making about AMR.   
2.1 The burden of infectious diseases  
In general, as countries become more developed their infectious disease burden falls and 
rates of non-communicable diseases rise (32). However, whilst the number of deaths 
associated with communicable diseases are slowly falling, infectious diseases remain 
important causes of illness and death, especially in low income countries (32, 33). In 
2017, communicable, maternal, neonatal and nutritional causes accounted for 18.6% of 
deaths worldwide (10.4 million deaths) (33).  
Despite New Zealand being a high income country, infectious diseases are still prevalent 
here and their burden is increasing (34, 35). Between 1989 and 2008, hospitalisations 
associated with infectious diseases increased in both absolute and relative terms (34). In 
1989-93, infectious diseases contributed to 20.5% of acute admissions, and this rose to 
26.6% in 2004 - 2008 (34). Infectious diseases are also a source of ethnic and social 
inequalities in health (34). The young and the elderly, those who are socioeconomically 
deprived, and Māori and Pacific peoples are disproportionately affected (34, 35). These 
inequalities in the burden of infectious diseases have increased significantly over the past 
two decades, especially for Māori and Pacific peoples and those who are in the most 
socioeconomically deprived quintile (34).  
2.2 Antimicrobial resistance 
Antimicrobial drugs are medicines that work against infections caused by micro-
organisms (36), and include antibiotics, antivirals, antifungals and antiparasitics (14). 
Antibiotics tend to work by inhibiting the production of proteins or cell wall materials, 





resistance occurs when micro-organisms (including bacteria, viruses, fungi and parasites) 
survive exposure to a medicine that would usually kill them or halt their growth (14, 37, 
38). Resistant strains can flourish and spread as susceptible strains are killed (14, 36, 39). 
The rapid development of bacterial resistance to antibiotics is of particular concern (19, 
40), with virtually untreatable bacteria now reported (41, 42).  
Antimicrobial resistance is a natural phenomenon (14, 40), but is becoming much more 
common. Many antimicrobial drugs are naturally produced by fungi or bacteria, and 
resistance genes have therefore existed in the environment since long before humans 
started using antibiotics (36, 43, 44). Resistance is a Darwinian selection process that 
allows microorganisms to survive exposure to many toxic substances (17), and is caused 
by mutations in microbe genetic material or acquisition of resistance genes from other 
microbes of the same or different species (45, 46). Alexander Fleming, the discoverer of 
penicillin, warned about the potential for development of resistance to antibiotics in 1945 
(47, 48). Bacteria may acquire a variety of genes that code for different resistance 
mechanisms, and thus become resistant to multiple antimicrobial agents, which 
drastically limits options for treatment (45). Historically the progression of AMR was 
slow and generally manageable by creating new drugs (14), but misuse and overuse of 
antibiotics has drastically increased the rate of development and spread of resistance (1, 
36, 43).    
To complicate the situation further, once resistance genes and their genetic vectors have 
evolved, they may indirectly spread through commensal, environmental, and pathogenic 
bacteria to reach bacteria anywhere else (13). Resistance genes can be incorporated by 
an individual’s natural microbiota and later be transferred to infecting pathogens (14). 
Resistance mechanisms can sometimes result in resistance to agents from many classes 
(cross resistance), or genes encoding resistance mechanisms may be transferred together 
(co-resistance) (4). 
2.3 Public health significance of antimicrobial resistance  
AMR is one of the greatest global threats to health in modern times (40, 49), with serious 
implications for modern medicine as a whole (7, 42, 50). As well as threatening our 





of modern medicine that require effective antibiotics, including surgery, dialysis, 
neonatal intensive care, and immunosuppressive therapies (5, 36, 40, 42, 49, 51, 52). It 
is estimated that at least 700,000 people die every year from resistant infections 
worldwide (38). Multi-drug resistant infections cause an estimated 25,000 deaths in the 
European Union every year, with associated health care costs and productivity losses of 
at least 1.5 billion euros (4).  
The Review on Antimicrobial Resistance (commissioned by the UK prime minister in 
2014, often referred to as the O’Neill Report) predicts that in the absence of urgent action, 
AMR will result in at least ten million deaths a year by 2050 (more than the projected 
burden of cancer), with an estimated global cost of up to 100 trillion USD (36). 
Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
Enterococcus (VRE), extended-spectrum β-lactamase-producing Enterobacteriaceae 
(ESBL-PE) and carbapenemase-producing Enterobacteriaceae (CPE) are key bacterial 
threats (50). The 2017 Global Burden of Disease Study noted rapid increases in death 
rates between 2007 and 2017 associated with extensively drug resistant tuberculosis, 
cellulitis, and C. Difficile diarrhoea, citing antibiotic use and resistance as a likely major 
factor (33).  
Bacterial resistance to antibiotics for a range of common diseases is becoming a 
significant threat to health in New Zealand (42, 53, 54). Resistance to major antibiotic 
classes including penicillins, fluoroquinolones and third-generation cephalosporins is 
now widespread in New Zealand hospitals, and is also increasing in the community (49). 
Community-associated MRSA, bacteria producing ESBL (e.g. E.coli and Klebsiella 
pneumonia) and multi-resistant Neisseria gonorrhoeae are all increasing in New Zealand 
(42). There is some evidence of ethnic inequities in the prevalence of AMR among those 
with infections, with AMR being higher among Māori and Pacific peoples (55). 
Antimicrobial use and overuse is said to be the primary contributor to the threat of AMR 
in New Zealand, and has been increasing in New Zealand in recent years (42). Total 
antibiotic consumption increased by 49% between 2006 and 2014 (52). Antimicrobial 
use  has been shown to be higher among people who live in more deprived areas (56) and 





antibiotic consumption in New Zealand was greater than 22 of 29 European countries 
that had surveillance data available (52). 
2.4 The complexity of antimicrobial resistance 
The main risk factor for development and acceleration of AMR is the overuse and 
inappropriate use of antibiotics (5 p.11), with data showing a direct correlation between 
antibiotic use and resistance (58). Higher resistance rates are observed in countries with 
high levels of antibiotic use (59). However, the emergence and spread of resistance is 
highly complex and there are many gaps in our knowledge (15). There are human, animal 
and environmental reservoirs of AMR, with complex transmission pathways between 
them (60). Major risk factors for the emergence and spread of AMR include antimicrobial 
use in humans and animals, environmental contamination, poor infection prevention and 
control practices, and poor sanitation, alongside globalisation that facilitates the spread 
of infections (11, 45). 
 The absence of new antibiotics 
Rapid development of resistance is now combined with a situation of few new antibiotics 
on the market (61). From 1940-1990, emerging resistance was managed by discovery of 
new antibiotics (62, 63). However, there are now limited numbers of new antibiotics in 
the pharmaceutical development ‘pipeline’ (1, 4, 47, 58), and it is clear  that we cannot 
rely solely on the development of new antimicrobials to address AMR (14). The slowing 
of antibiotic development has been attributed to scientific challenges in antibiotic 
discovery (14, 62), licensing issues (62), increased regulatory requirements (63) and 
decreasing investment in antibiotic research and development (64, 65). Major 
pharmaceutical companies may be reducing investment due to the limited profitability of 
antimicrobials, particularly compared with development of drugs for chronic medical 
conditions (63, 64, 66). The impact of resistance on current and future antibiotic sales as 
well as the current questioning of the utility of antibiotics for many conditions for which 
they were previously widely prescribed all contribute to this limited return on investment 
(63, 66). For pharmaceutical companies, antibiotic development is a situation of high 





 Antibiotics and AMR in human health 
Antibiotics comprise some of the most commonly prescribed medicines in human health, 
but up to 50% of this may be unnecessary or sub-optimal prescribing (5). A perception 
of antibiotics as ‘wonder drugs’ is problematic (40). Inappropriate prescribing has been 
associated with rising rates of antibiotic resistance (44, 67), with much of this occurring 
in primary care (59, 68). Antibiotics are overused for many conditions, particularly for 
respiratory tract infections, which are often viral in origin (58). Physician-related factors, 
patient-related factors and healthcare system factors may all influence prescribing (67). 
Patient understanding and education about antimicrobials, as well as behaviours such as 
not completing recommended treatments and stockpiling antimicrobials, may all 
contribute to AMR (68). Antibiotic resistance can be a particular problem in countries 
where antimicrobials are available without prescription or where generally poor 
sanitation results in increased transmission of infection (1, 44).  
Prescribing behaviour has been found to be influenced by a number of factors, including 
physician experience, knowledge about AMR, diagnostic uncertainty, time pressure, and  
fear of losing clients if the patient’s expectations of getting a prescription are not fulfilled 
(67). For example, a study found that whilst doctors knew antibiotic prescriptions tend 
to be of limited usefulness for sore throats, antibiotics were often prescribed to build and 
preserve relationships (69). In other studies, doctors’ perceptions of patient expectations 
of antibiotics were strong predictors of the decision to prescribe (68, 70, 71). However, 
studies have also found that this perception of patient expectations can often be incorrect 
(58, 69). Communication between physicians and patients could be key for bridging gaps 
in expectations (58). 
 AMR in food animals – a threat to human health? 
The AMR crisis in human medicine has resulted in urgent questioning about the various 
other uses of antimicrobial drugs, including their use in food and companion animals (8, 
61, 65). Many classes of antimicrobials used in animals (both food and companion) are 
also used for human medicine (12). Antibiotics are widely used in food animals for the 
purposes of disease prevention, control, and treatment, and for growth-promotion or 
feed-efficiency (5, 72, 73). In some countries the volume of antibiotics used in food 





farming of food animals (large groups and high densities), which favours animal 
production practices associated with the use of large quantities of antibiotics (14, 65). 
This may increase selection pressure on bacteria, facilitating the emergence of resistance 
(8, 73, 74). Entire herds or flocks of animals are often treated with antibiotics, in contrast 
to humans usually being treated as individuals, which adds another level of complexity 
(14). An estimated 63,151 tonnes of antibiotics were used for animal agriculture 
worldwide in 2010, and this is predicted to rise by almost 70% by 2030 (73). 
There is significant debate about whether antibiotic use in food animals results in 
resistant infections in humans (46, 61, 72). Numerous possible transmission pathways 
have been suggested, including that gut bacteria in food producing animals may 
contaminate meat during slaughter or enter the environment in animal waste, with 
possible contamination of soil, water and crops (75). The severity and relative impact of 
risk to human health has not been well characterised (65), possibly in part because “given 
divergent stakeholder interests and inadequate research to date, public policy 
discussions of this issue are often contentious and highly polarized” (65 p.5). However, 
there is widespread recognition (including by international organisations such as the 
World Health Organisation, the Food and Agricultural Organisation of the United 
Nations (FAO), and the World Organisation for Animal Health (OIE)) that antimicrobial 
use in food animals poses a risk to human health, and should be approached more 
judiciously (15, 16, 36, 72, 74, 76).   
Use of antibiotics for enhancing production is seen as especially problematic (14, 16), 
with particular risk attributed to their continuous, low-dose non-therapeutic applications 
such as growth promotion and disease prevention (5, 9, 16, 47, 72, 77). The regulation 
of antimicrobial use in food animals varies worldwide (77). The most stringent guidelines 
ban the use of antibiotics for growth promotion, and require veterinary prescription for 
antibiotic use (e.g. in the E.U.) (77). Antimicrobial use in food animals in Denmark has 
reduced by 54% as a result of banning antibiotic growth promoters (74).  
A recent review found compelling evidence to support each step in the causal pathway 
from antimicrobial use in animal agriculture to resistant infections in humans (15). Other 





originate in food-producing animals (75, 78). On the other hand, some question the 
completeness of the evidence (46, 79). Some authors discuss how banning antimicrobial 
growth promoters has led to reductions in resistant bacteria prevalence in food, food 
animals and humans (74), whilst others say such bans have had limited success and can 
result in worse animal health, and a paradoxical increase in human illness and resistance 
rates  (61, 80). Rising use of antimicrobials in aquaculture is also a concern, being a 
potential source of contamination of the aquatic environment (72, 73). 
 Companion animals and AMR 
More attention is beginning to be focused on antimicrobial use and bacterial resistance 
in companion animals (8, 81). Companion animals have uniquely close contact with 
humans (81), and they may share resistant bacteria, amplify resistant bacteria they 
acquire from people, or act as a reservoir for human infection (8). Current knowledge of 
magnitude of these health risks is limited (81). The use of antimicrobial drugs in 
companion animals is less regulated compared to food animals (8). Much less attention 
has focused on the impact of AMR acquired by humans from companion animals 
compared with food animals, and thus may be considerably underestimated (8). 
However, the emergence of MRSA in companion animals has increased interest in their 
role in the AMR system (8). 
 The environmental dimension of AMR 
The environment is also an important reservoir of resistance genes including naturally 
occurring resistance, resistance present in human and animal waste, and resistance 
resulting from co-selection by pollutants (10). The environment has historically been an 
under-recognised dimension of AMR (60).  Here I define the environment as including 
inanimate aspects of the natural and built environment, as well as plants and wildlife, 
which are often considered part of the wider ‘ecology’. Antimicrobials can persist largely 
unchanged for some time in the natural environment (1). Antibiotics excreted by humans 
or animals that enter the environment can exert selection pressure below therapeutic 
concentrations, which is ideal for selecting for resistance (44). Antibiotic manufacturing 
plants can be another important contributor to AMR in the environment, especially in 





Antibiotics are used in relatively small amounts for disease prophylaxis in horticulture 
(82) and may also contaminate animal manure that is used as fertiliser for crops (83). 
Humans may be exposed to antibiotics, resistance genes or resistant bacteria present in 
the environment through a variety of routes, including: crops exposed to contaminated 
sludge, manure and slurry; infected livestock products; contaminated fish; contaminated 
drinking water with pharmaceutical residues; and contaminated coastal waters (10). 
Wildlife (often considered part of the environment) can also be reservoirs of AMR (60). 
Resistance is made more complex by the phenomenon of co-selection. Co-selection 
occurs when a resistance determinant is associated with other kinds of adaptations, such 
as resistance to heavy metals (84). For example, environmental contamination by heavy 
metals such as copper can directly select for heavy metal resistance and, at the same time, 
indirectly for antibiotic resistance (46). Antibacterials present in many household 
products can also enter the environment and exert selection pressure, altering the wider 
microbial ecology (44). Figure 2.1 from Wellington et al. (2013) summarises some of 
the key environmental reservoirs of AMR and their connections with humans and 
animals.  
Figure 2.1 Environmental reservoirs of resistance genes: the associations between 
potential sources of antibiotic resistant bacteria (Wellington et al., 2013)1  
                                                 
1 Reprinted from The Lancet Infectious Diseases, Volume 13, Wellington et al., ‘The role of the natural 
environment in the emergence of antibiotic resistance in gram-negative bacteria’, p. 155-165, Copyright 





 Antimicrobial use in human and animal health in New Zealand 
In 2013, total antibiotic consumption in human health care in New Zealand was greater 
than 22 of the 29 European countries with antibiotic consumption data available (52). 
Antimicrobial use for food animals is less prevalent in New Zealand than other countries, 
but the authors cautioned that use in this sector could still be further refined. When 
compared with 26 European countries, Australia, Canada and the United States of 
America in 2012, New Zealand’s use of antimicrobials in animal production was third 
lowest (an estimated 9.4 mg active ingredient/kg biomass) (11). Use of antimicrobials in 
humans was 12.9 times the use in animals in New Zealand (11). 
2.5 The need for an integrated approach to AMR 
It is clear from the above discussion that AMR is a highly complex issue with human, 
animal and environment dimensions. However, despite AMR being called “the 
quintessential One Health problem” (7), the relative contribution of the three domains in 
the creation and perpetuation of the AMR problem is poorly understood (7). Although 
there is acknowledgement that the prevalence of AMR is determined by a complex 
network of factors, most research currently focuses on one or two parts of the network. 
Quantifying the relative contribution of each sector to the problem of AMR is difficult 
(15, 46, 61). Lack of data feeds this ongoing debate regarding which sector contributes 
the most to the acceleration of AMR, and slows the response of each in taking action 
(14). In addition, a better understanding of the political and economic context is needed 
for effective policy-making – this is just as important as the scientific evidence base  (85). 
This wider understanding is lacking in much AMR research and strategy. 
There are increasing calls for integrated systems approaches to address antimicrobial 
resistance (86-89), because it is in these connections and relationships that important keys 
to the problem may be found. There is also recognised need for models that show the 
complexity and dynamics of inter-relationships between elements of the wider system 
(86-89). Models of AMR have often been centred on one domain (e.g. the hospital 
setting) and usually focused on a small number of proximate factors, rather than taking a 






In summary, antimicrobial resistance is an important and growing public health threat, 
with inequitable distribution in New Zealand and globally. Human, animal and 
environmental settings are all involved in the problem, but there is debate about their 
relative importance, which slows effective action on AMR. There is increasing 
recognition of the need for research and policy approaches that integrate these 
dimensions of AMR (such as One Health approaches) in a systematic way. In the next 
chapter I describe a literature review of existing research that responds to the above calls 






3 Literature review of AMR causal models  
As established in the background chapter, there is a need for integrated systems 
approaches to address antimicrobial resistance (86-89). Important solutions to the 
problem may be found by exploring the connections between variables in a system. 
Systems approaches often involve the creation of a model, which is a simplified 
representation of complex processes, to improve understanding (91). The aim of this 
literature review was to identify previous research that has modelled the AMR system, 
integrating human, animal and environmental dimensions of AMR in a way that 
represents a high-level causal theory about the problem.   
A systematic, comprehensive search strategy and inclusion/exclusion criteria were used 
to establish the extent of the literature describing causal models of AMR that involve 
elements from two or three of: human, animal and environment settings. Given the One 
Health and EcoHealth underpinnings of this research, the focus was on identifying 
models that integrate human, animal and/or environment disciplines rather than those 
that only incorporate a single domain. Models intended for influencing policy decisions 
were of particular interest. Further aims were to identify what modelling techniques have 
been used, what questions have been asked, and where the knowledge gaps are, as well 
as to critically assess the quality of included studies.   
As identified in the background chapter, models of AMR have often been centred on one 
domain (e.g. the hospital setting) and usually focused on a small number of proximate 
factors, rather than taking a broader approach to identifying systemic drivers of the 
problem (90). Examples include modelling of bacterial population dynamics and the 
emergence of multidrug resistance (39, 92), and the emergence and/or spread of resistant 
bacteria in a community/population (93, 94). There are many correlational modelling 
studies about AMR, for example comparing genetic markers of resistance between 
animal and human populations (95, 96).  
Mathematical modelling approaches have been used to further understanding and support 
public health decision-making relating about the emergence and spread of resistant 





perspectives, presenting a biological view of the problem (97).  Such models have been 
used to explore the relationships between antibiotic exposure and resistance 
development, and concepts of antibiotic tolerance and microbial fitness (97) and to model 
dynamics of person-to-person agent transmission (98).  
While the types of models described above can provide useful insights, it is also 
important to create models that show the complexity and dynamics of inter-relationships 
between elements of the wider system, as part of an integrated systems approach, to 
support effective policy-making (86-89). This review aimed to identify such studies.  
3.1 Review Methods 
 Search strategy and study selection 
Using a purposive search strategy, I searched Web of Science and Scopus databases using 
the following search terms: 
(("participatory model*"  OR  "participatory epidemiology"  OR  stakeholder )  OR   
( "systems thinking"  OR  "systems approach"  OR  "system dynamics"  OR  "systems 
mapping"  OR  "complex system"  OR  "dynamic complexity" OR “system model*” OR 
“dynamic model”) )  OR   
 ("one health"  OR  onehealth ) OR   
(ecohealth  OR  "eco health"  OR  "ecosystem approach*"  OR  "ecosystem health" )) 
AND 
("antimicrobial resistance"  OR  "antibiotic resistance" )  
 
One Health and EcoHealth terms were used in the search as they are increasingly used 
integrative research approaches, with a focus on systems-level thinking and integration 
of human, animal and environmental health (23, 99). The initial intention was to search 
for synonyms of the EcoHealth principles (explained in detail in section 4.2.2) and AMR, 
however this process returned over 64,000 results. Eventually terms related to 
transdisciplinary, justice and sustainability were excluded as they did not return relevant 
results for this search. Systems thinking and modelling phrases and synonyms were 
included, as well as EcoHealth and One Health synonyms. ‘Integrative’ search terms 





relevant had been found by the previous search terms. ‘One Health’ was used as a proxy 
for human, animal and environmental health combined, as it was found that searching for 
‘human AND animal AND environment’ was too broad to be useful. The search strategy 
was also validated by ensuring that the four existing papers I was aware of through 
background reading and supervisory recommendations were all included in the search 
results.  
Web of Science and Scopus were chosen as the most relevant databases for the research 
area and question due to their interdisciplinary nature, and following testing of various 
databases for relevancy of results, and consultation with a librarian. A small number of 
papers were recommended by supervisors of the project or had been found during 
previous background research. Grey literature searching included a search of the System 
Dynamics Review conference proceedings to check for modelling papers about AMR 
that may not have been published in a journal. This involved searching for “antibiotic 
resistance” or “antimicrobial resistance” within all available paper lists. All records were 
managed in Endnote X8. 
All retrieved results were screened by title, and papers that clearly did not relate to the 
research question were excluded. The remaining articles were assessed by screening their 
abstracts. If there was any uncertainty about how relevant the papers might be, they were 
retained for further assessment of the full text. The remaining articles were assessed for 
eligibility by reading the full text. The reference lists of included papers were also 
screened for further relevant articles. 
 Criteria for inclusion of studies 
To be included in the review, studies had to be specifically or mostly about antimicrobial 
resistance/antibiotic resistance. They had to include a causal-descriptive model (defined 
below) of the AMR system that integrates two or more of human, animal and 
environmental aspects of the problem, with an illustrative diagram. Papers had to be 
written in English, as translation costs were not feasible for this thesis. Results were not 





Studies were excluded if they did not model AMR or if the model was not a causal theory. 
Studies that modelled the AMR system in one setting only or at a micro-level (e.g. 
bacterial population dynamics/transmission of AMR in a hospital ward/epidemic models) 
were also excluded. For this review the aim was to find studies that model AMR as an 
entire system, especially including social, political and economic aspects (here called 
‘high-level drivers’). Therefore, mechanistic models of biological processes of resistance 
selection and transmission were excluded. These represent more detailed, micro-level 
models rather than broader systemic drivers that might assist policy-makers in the face 
of complexity. Mathematical correlational models were also excluded from detailed 
analysis as they do not meet the causal theory criteria.  
For the purposes of this review, a model is defined as “a representation or a construction 
of a reality” (100 p.450). Barlas (1996) distinguishes between ‘causal-descriptive’ 
models which are theory-like models, and models that are purely ‘correlational’ (data-
driven). Causal-descriptive models provide claims about causality through their 
structure, which can be openly interrogated (‘white box’). In contrast, purely 
correlational models focus on the aggregate output of the model, while the structure may 
be obscure (‘black box’). Correlational models are mainly used for forecasting purposes 
(e.g. time-series and regression models), while causal-descriptive models are theories 
about the operation of a system. For causal-descriptive models, the internal structure of 
the model is crucial to validity (101).  As well as reproducing and predicting the 
behaviour of a system, the model must also be able to explain how the behaviour is 
generated, and perhaps suggest ways of changing this (101). To be included in this 
review, models had to specify causal relationships between variables in a model of AMR.  
 Data extraction and assessment of quality and validity 
For each of the full text articles assessed, notes were made in a standardised template 
(Appendix A) about their background, methods, results, discussion, and further 
references to look at. A comment about their overall relevance to the literature review 
was made, as well as which of human/animal/environment dimensions were included, 





For those studies that met the inclusion criteria for this review, I assess whether the 
quality and validity of the models has been reported on. Criteria for assessing the quality 
of causal models are sparse and authors may not report on quality criteria in their 
published papers. However, Schwaninger and Grösser (2008) build on  previous work to 
present ten criteria for assessing the quality of a model-based theory: refutability, 
importance, precision and clarity, parsimony and simplicity, comprehensiveness, 
operationality, validity, reliability, fruitfulness and practicality (100). Coyle (1996) 
provides a similar set of criteria: clarity and usefulness of purpose, suitability, basis, 
credibility, creativity, simplicity, redundancy, transparency, flexibility, generality, 
sensitivity, soundness, productivity and promotion (102).  Whilst there is overlap in the 
quality criteria from different sources, there appears to be no standardised method of 
assessing the quality of models.  
Of the aforementioned quality criteria, very little detail is provided on their meaning and 
assessment. Detail on assessing the validity of models is most common, therefore validity 
was the main focus of quality assessment in this review. Even so, validity is rarely 
discussed (101). It has most often been considered in system dynamics (SD) modelling. 
Since I was unable to find an article that includes general criteria for assessing the validity 
of causal-descriptive models, principles of validity that relate to system dynamics models 
were applied. There are some articles available on assessing the validity of this type of 
causal model, and the majority of the articles found in the literature review that were 
most relevant to my research question used system dynamics modelling. In contrast to 
the relative simplicity of assessing correlational models, assessing the validity of causal-
descriptive models can be complicated for both technical and philosophical reasons (see 
Barlas, 1996 for more). 
The validity of a model is how accurately it represents the system under study (100). 
Model validation has both semi-formal and subjective components (101). For causal-
descriptive models (a theory about a real system), questioning the validity of the internal 
structure of the model is crucial – it must accurately explain how the behaviour of the 
system is generated (101). In the context of system dynamics modelling, Forrester and 
Senge (1980) define validation as “the process of establishing confidence in the 





confidence in the model (100, 103, 104), and involves addressing questions of model 
usefulness in relation to purpose, and structural validity (101, 105, 106).  
A model builder uses validation processes to build confidence that the model behaves 
plausibly (106). Confidence about its usefulness is built as the model withstands attempts 
to disprove it (106, 107).  In order for a model to be useful in enhancing understanding 
of a problem and contributing to more effective policies, there must be a communication 
process with a target audience that transfers confidence in the model to those not directly 
involved in constructing it (106). Usefulness can be assessed by questioning both the 
modelling process and outcomes of the model’s use (108).  
Assessing internal validity involves iterative tests of model structure and behaviour 
(103), of which structural validity is most important to establish first (101, 109). Each 
detail of the model structure must be examined to judge the merit of the included 
variables and how well they have been connected (103). Behaviour accuracy - how well 
the model reproduces the major behaviours shown in the real system (101) - can be tested 
following satisfaction that the structure of the model is adequate.  
For each of the included studies, in the results section of this review I comment on 
whether the authors discussed how the model was built, whether authors reported 
assessments of quality and validity, and whether any formal validation procedures (tests 
of model structure and behaviour) were carried out. I also make an assessment of the 
model’s usefulness in relation to purpose. In some cases, lack of information about these 
aspects prevents comprehensive comments. 
 Synthesis of data 
For those studies that met the inclusion criteria, I tabulated information about modelling 
methods used, number of domains (human/animal/environment) covered, process for 






3.2 Review results 
See Figure 3.1 for a flow diagram of the search process and results, based on the preferred 
reporting items for system reviews and meta-analyses (PRISMA) (110). Most of the 
records identified through the search were found in Web of Science (360 articles) and 
Scopus (520 articles) databases. No relevant papers were found among the reference lists 
of the included papers (392 references). 
 
Figure 3.1 Flow diagram of search process and results, based on PRISMA guidelines 





The search of the System Dynamics Review conference proceedings found a further two 
records, and two others were recommended or found during previous research. After 
removal of duplicates, 613 records remained for screening by title. At this point 539 titles 
were excluded, mostly because they did not integrate more than one dimension of AMR. 
The resulting 74 articles were screened by reading the abstract. Sixty-one of these were 
excluded. The main reasons for exclusion at this stage were that the papers did not 
describe a model of the AMR system (although many did mention two or more of human, 
animal and environment aspects in passing, and highlight that AMR is a complex 
problem).  
This left 15 full text articles to be assessed for eligibility to be included in the review. 
Upon reading the full text, only six of these articles were eligible to be included for 
detailed review. I therefore briefly summarise the nine articles excluded on full text 
review below. 
One abstract (92) was excluded as the full text could not be found. This appeared to be 
an extension of the study described by Homer et al., 2000. Two mathematical modelling 
studies relating to the transmission of resistance between food animals and humans (111, 
112) were excluded as they did not meet the causal theory criteria. Four articles were 
excluded from further analysis as they only modelled within one domain or setting (39, 
92-94). Two of the papers (86, 87)  strongly advocated for a systems approach to learning 
about and addressing AMR, and discussed the importance of integrating human, animal 
and environmental aspects of AMR. However, they did not provide cause and effect 
models of AMR and were therefore excluded. It is worth mentioning that other articles 
did discuss the idea of AMR as a complex system and involving links between the three 
areas. However, they did not include models of AMR and were therefore excluded. 
This process of exclusion left only six papers that closely matched the inclusion criteria 





Table 3.1 Characteristics of included models 
Reference Focus (domains) Model type Process for building model Purpose of model 
Homer et al., 2000 
(39)  
Mostly human aspects, 
some animal aspects 
Causal loop diagram 
(qualitative SD model)  
Limited information about process, 
but involved a group of experts 
To display AMR problem 
structure and policy loops 
Cox and Ricci, 
2008 (80) 
Mainly human and animal 
(food chain transmission of 
resistance), with small 
environment link 
Quantitative SD model, 
with a simple qualitative 
directed acyclic graph to 
illustrate 
Six proposed causal relations 
justified by reference to historical 
trends/the literature 
Quantitative risk assessment 
modelling -to assess likely effects 
of a ban on animal antibiotic use.  
So et al., 2015 (89) Transmission from 
livestock to humans, with 
the environment as one 
possible pathway 
Conceptual model  Not entirely clear. Cites one study To display pathways of 
transmission of ABR from animals 
to humans 
Grohn et al., 2017 
(88) 
Human and food animal 
aspects 
Qualitative model with 
some SD features 
Limited information available To illustrate boundaries of the 
food supply system to be modelled  
Majowicz et al., 
2018 (90) 
Human, animal and 
environment (in context of 
Canadian food chain) 
Qualitative SD 
conceptual model. 
High level of 
complexity 
Diagramming of factors impacting, 
or impacted by, use and resistance 
along the Canadian food chain. 
Using group model building and 
expert elicitation within the author 
group 
To identify stakeholders not 
traditionally engaged in 
mitigating AMR who could play a 
role  
Henriksson et al., 
2018 (113) 
Human and animal 
(aquaculture) factors. Small 




Identifies main factors behind AM 
use in aquaculture, providing 
evidence from the literature to 
support each. Then combines this 
information in a summary diagram 
Summarise underlying and 
proximate driving factors of AM 
use in aquaculture globally. To 
help identify possible 





 Design of included models 
Three of the models had some features of qualitative system dynamics models (39, 88, 
90), one was described as a quantitative system dynamics model (with a qualitative 
illustrative diagram) (80), and two were linear conceptual models (89, 113). One model 
was specific to Canada (90), whilst the other models were not specific to a particular 
country. I will now discuss each in more detail. 
Homer et al., 2000 
The earliest relevant model was from 2000 in a paper by Homer et al. (39). The paper 
was mostly about modelling bacterial population dynamics, however they did include a 
diagram illustrating the wider complexities of the problem (Figure 3.2). 
This diagram was based on a 1998 meeting between the Infectious Disease Epidemiology 
and Surveillance Division of the Texas Department of Health (TDH), and the Strategic 
Decision Simulation Group, which “assembled a group of experts to begin thinking 
systemically about the problem of antibiotic resistance and possible policy options at the 
state and national levels” (39 p.288). The diagram is policy oriented. It includes policies 






such as education and regulation, and simulation modelling was employed to look at 
specific policy options. Homer et al. include a version of the causal loop diagram 
produced from the meeting, but do not provide details about the model building process. 
I was unable to find any further information about the diagram or how it was produced.  
The model includes human social, political and economic factors involved in 
perpetuating antibiotic resistance, but also includes a few variables related to animal 
husbandry and use of antibiotics in food animals. Environmental aspects are not present. 
Six feedback loops can be identified in the diagram: ‘contagion spiral’, ‘surveillance-
funding spiral’, ‘basic use of AB for treatment’, ‘R&D response’, ‘cost containment 
response’ and ‘AB resistance-use spiral’. It is not clear whether ‘regulatory response’ 
and ‘education response’ are feedback loops. However, while this diagram represents a 
causal theory in that arrows between variables represent causal relationships, the exact 
nature of these relationships (+/-) and the type of feedback loops (reinforcing or 
balancing) are not specified, which is unusual for a causal loop diagram. This model 
illustrates that as long as two decades ago, systems modelling was viewed as a potentially 
helpful way of better understanding antibiotic resistance. 
Cox and Ricci, 2008 
Cox and Ricci (2008) describe a quantitative system dynamics model of bacterial flows, 
with the aim of explaining how banning the use of antibiotics in animal agriculture may 
paradoxically increase resistance in humans (and is therefore implicitly policy oriented) 
(80). The article begins with a regulatory analysis of precautionary legal requirements, 
making the argument that precautionary bans of animal antibiotics in Europe were a 
result of more political will than empirical evidence. The quantitative model consists of 
six proposed causal relations represented by ordinary differential equations. However, 
the qualitative diagram used to illustrate the model (Figure 3.2) is a directed acyclic graph 
(DAG). By definition, a DAG is a causal theory that stops time – it is not dynamic and is 
not allowed to incorporate feedbacks. Therefore, this diagram may indicate that the 






The variables involved in this simple model include the fraction of humans with a specific 
foodborne illness (IH), ill animals (IA), resistant infections in humans (RH), resistance 
contamination of animal food products (RA), and animal antibiotic use (A). Transmission 
of resistance via the environment is mentioned as possible links between some of these 
variables. A set of equations represents this model quantitatively, and indicates that a ban 
of animal antibiotics can increase resistance in humans, if said ban results in a sufficiently 
large increase in sick animals, and therefore sick people.  
So et al., 2015 
So et al. (2015) include a linear conceptual model (89). This is a simple overview of 
transmission pathways of antimicrobial resistance between animals, the environment, 
and humans (Figure 3.4). The main focus is illustrating how resistance in food animals 
may pass to humans. Influencing policy does not appear to be an aim of the diagram. The 
process for developing the model is not described, but it appears to rely on one cited 
source about cross-species transmission. 
Figure 3.3 DAG of the relationships between antibiotic use in animals and resistant 






Figure 3.4 Transmission pathways model (So et al., 2015) 
Grohn et al., 2017 
More recently, Grohn et al. (88) described a multi-disciplinary effort to create a 
framework to analyse the impact of the policy of restricting use of antibiotics in animals 
– to evaluate how antimicrobial use interventions impact on AMR. A systems approach 
was decided upon due its suitability for supporting decision-making and evaluating 
interventions for complex systems. The authors point out that no suitable integrative 
model of AMR existed that could be used to assess the policy. The authors use a systems 
approach to understanding drivers of AMR. The paper includes an overview model which 
met the criteria for this review (Figure 3.5). This is a qualitative model used for the 
purpose of illustrating the boundaries of their particular research question. It has some 
characteristics of a qualitative system dynamics model, though it was not described as 
such (Figure 3.5). The polarities of the arrows, incorporation of feedback and indication 
of time delays are features of SD, but the feedback loop (relating to media attention and 
public awareness) is not explicitly labelled. There is some inclusion of policy-related 
variables, such as ‘initiatives of livestock industries’. In later parts of the paper they 
describe modelling including pharmacodynamic/pharmacokinetic modelling of the 
exposure of bacteria to antimicrobials, and the likely effect of such selection pressure on 
AMR in meat (these types of models did not meet the criteria for inclusion in this review). 






Figure 3.5 Boundary setting system dynamics model (Grohn et al., 2017) 
Majowicz et al., 2018 
Majowicz et al. used a system dynamics modelling methods to diagram factors 
impacting, or impacted by, antimicrobial use and resistance along the Canadian food 
chain (90). The authors contextualise AMR as an issue involving people, animals and the 
environment, but narrow their model focus to the food chain. Variables and relationships 
were identified using group model building and expert elicitation processes within the 
author group (90). The purpose of the model was to identify stakeholders not traditionally 
engaged in mitigating AMR who could play a role, whom researchers and policymakers 
could work with. This was determined by identifying individuals or organisations who 
act on the factors in the model.  
The process began with a simplistic representation of AMR in the food chain and its links 





scenario to the draft model. Further refinements yielded the final conceptual model 
shown in Figure 3.6. 
Although it has been drawn using qualitative SD principles, the diagram does not identify 
feedback loops (purposeful identification of feedback loops is standard practice in SD 
modelling). Therefore, it is arguable whether the resulting diagram can be called a true 
SD model. However, upon close inspection a number of potential feedback loops can be 
seen within Figure 3.6, for example: population vulnerabilities increases HIV and other 
infectious diseases, which increases population vulnerabilities (reinforcing loop); on-
farm AM use reduces livestock illness, which reduces use for preventive purposes, which 
reduces on-farm AM use (balancing loop). The complexity of the diagram makes it 
Figure 3.6 Qualitative system dynamics model of AMR in the Canadian food chain 






somewhat difficult to decipher the relationships and overall message, but it successfully 
meets its stated purpose of facilitating the identification of a range of non-traditional 
stakeholders in the issue of antimicrobial use and resistance in the Canadian food chain. 
The model illustrates complexity and the variety of factors involved, rather than 
portraying a refined causal theory that can be used to influence policy making.  
Henriksson et al. (2018) 
Figure 3.7 from Henriksson et al. shows a linear conceptual model of inter-linkages 
between underlying drivers and antimicrobial use in aquaculture through a set of 
proximate factors (113). The purpose of the diagram is to summarise the most influential 
underlying and proximate factors driving antimicrobial use (and therefore resistance) in 
aquaculture. They are structured in a hierarchal manner ranging from the individual 
animal to international policy level. The model includes an important positive feedback 
loop between resistance and antimicrobial use (more resistance leads to more 
antimicrobial use, which leads to more resistance), which is further discussed in text.   
The model is based on the preceding text, which identifies the main factors driving 
antimicrobial use in aquaculture, providing evidence from the literature to support each. 
This model is not as specific about the nature of the relationships between variables as 
some of the previous models. It includes some reference to policy being part of the 






Figure 3.7 Conceptual model of drivers of antimicrobial use in aquaculture  
(Henriksson et al., 2017) 
 Domains covered 
Most of the models described above focused on the interplay between human and animal 
domains, with a focus on the food animals (80, 88-90, 113). Homer et al. (2000) had the 
least amount of focus on animals, and the most emphasis on high-level structural factors 
and policy responses to AMR. The environment domain was under-represented – 
although four of the models (80, 89, 90, 113) included some reference to the environment, 
this was not done in detail. 
The system dynamics model in Majowicz (2018) includes a multitude of human, animal 
and environmental factors, with a focus on the first two. A number of these are high level 
drivers, e.g. ‘corporate profits from AM’ and ‘public demand for alternatives to AM’. 
The main areas of interest for Cox and Ricci (2008) are the links between human and 
animal health, mainly via the food chain. Resistance in the environment is not a specific 
variable in the model, but is discussed as being on the pathway between variables (e.g. 
“Conjecture 2, antibiotic use in ill humans leads to increased resistance in the 





Henriksson et al. (2017) focus on antimicrobial use in aquaculture. Their model includes 
factors that are specific to animals (aquaculture), farmers and higher level 
services/government/policy (human-related factors). The environment is alluded to in the 
model in terms of influencing animal vulnerability to bacterial diseases, but further 
environmental aspects of AMR are beyond the scope of the model.  However, it does 
emphasise in text that AMR gene transmission goes beyond aquaculture, therefore 
requiring a One Health approach to AMR (113). The text points to an important link 
between AM use in aquaculture and AMR in humans, particularly as anthropogenic and 
livestock waste often end up in the aquatic environment.  
The model in the paper by Homer et al. (2000) mainly focuses on human aspects of the 
AMR problem, with a small inclusion of some livestock related variables. High-level 
factors such as ‘surveillance infrastructure’ and ‘dollars spent on R and D’ are included. 
The causal model in Grohn et al. (2017) specifically relates to the transmission of 
antibiotic resistance from livestock to humans (zoonotic factors), with inclusion of wider 
economic and social variables such as ‘alternatives to antibiotics’, ‘media awareness’ and 
‘public attention’. The causal model in So et al. (2015) focuses on the transmission routes 
of AMR from food animals to humans, with the environment as one possible pathway. 
 Model quality and validity 
Overall there was little attention paid to model validation or describing the basis for the 
relationships described, undermining the quality of the models. Only two papers 
described how they arrived at the relationships in their diagram with supporting evidence 
(80, 113). The others lacked robust validation against the existing literature or routinely 
collected data. One paper (80) had an explicit discussion of the validity of their model, 
and one (90) mentioned that further work would be needed to refine and validate the 
model. 
It is difficult to comment on the validity of the SD model included in the paper by Homer 
et al. (2000) due to the lack of information about the origins and process of building the 
model, beyond a brief mention of simulation modelling. The quality of the model is 
limited by the fact that traditional causal loop diagram symbology is not used; they omit 





feedback loops. Despite this, the diagram provides useful insights into the variety of 
perspectives on high level drivers of AB resistance, and highlights feedback loops that 
are not recognised in other articles.  
Cox and Ricci (2008) produced a Directed Acyclic Graph as part of their quantitative 
risk assessment. It seems to have been useful for its intended purpose, which was to 
inform a quantitative model to evaluate the possible impacts of banning animal 
antibiotics on human health. The assumptions behind the differential equations of the 
model are justified with reference to the literature. They make formal attempts to validate 
the model through testing implications of the model by comparison with historical data. 
The results of these tests reportedly support their conclusions but the authors note that as 
better surveillance data becomes available it will be necessary to re-test and refine the 
model (80). The model is useful in that it provides an overview of some key components 
and relationships linking human and animal health and resistance. However, given the 
small number of variables (five) in the model, it does not capture the complex or wider 
drivers of the problem. The complexity of the modelled equations make it difficult for a 
non-statistical expert to interrogate the nature of the relationships being modelled, 
limiting its ability to be validated or increase wider systems understanding. 
The conceptual model in So et al. (2015) is useful in that it highlights some simplified 
pathways of resistance transmission. Its quality and validity may be limited because it is 
based on only one cited source, but it does correspond with wider literature in terms of 
possible transmission pathways.  
The model in the Grohn et al. (2017) paper is useful in providing a transparent indication 
of what factors the authors consider are ‘within scope’ in later modelling steps. Some of 
the factors of interest were well described in the following text, and a variety of complex 
models were used to address these in later steps, including pharmacokinetic/dynamic 
modelling techniques. Grohn et al. (2017) devote some effort to discussing sources of 
model uncertainty, but this is not done specifically in relation to the model discussed in 
this thesis. Later in the paper the ‘factors not considered’ are described in more detail, 





The model in Majowicz et al. (2018) is useful in that it meets its purpose of aiding 
identification of non-traditional stakeholders who could be involved in mitigating AMR. 
It provides a transparent starting point for more in-depth model building (90). A factor 
that may weaken the validity of the model is that the relationships identified are based 
solely on the expertise of the author group. They acknowledge their perspective is biased 
towards public health, foodborne disease, veterinary medicine and livestock factors, and 
comment on the need to involve other kinds of experts to improve confidence in the 
model and validate it (90). A further recognised limitation is that constructing a higher 
level systems view of the problem has trade-offs with nuance and detail (90).  
Confidence in the model by Majowicz et al. is diminished by the fact there is no 
discussion of justification of the particular variables included and the nature of the 
relationships between them, beyond describing the process for building the model. 
However, the authors applied an example case scenario to their initial draft model to aid 
further refinement, which helps build some confidence in the model. The broader 
usefulness of the model is limited by the fact they did not go as far as specifying feedback 
loops in the diagram, and the complexity of the ‘spaghetti style’ diagram also limits 
comprehension. The type of SD model is not specified, other than to say it is a 
‘conceptual model’. They acknowledge that future modelling steps will need to include 
consultation with a wider group of experts, and validation processes.   
The model in Henriksson (2018) is a summary diagram of factors discussed in depth 
previously in the paper. The links between factors can be easily followed and understood 
and are supported by information and references given in the text. The model’s clear 
structure makes it a useful summary diagram about causal pathways leading to AM use 
in aquaculture. However, as the types of variables included in the model are quite broad 
and the exact nature of the relationships between the variables are not specified in the 
model, it would be difficult to formally validate the model. It seems to be a summary 
model rather than a model intended to be tested and verified. 
3.3 Summary and discussion of review results 
The aim of the literature review was to identify previous research that has modelled the 





in a way that represents a causal theory. Models that might have policy relevance were 
of particular interest. Only six studies met the criteria for inclusion in the review. Most 
were focused on modelling the transmission of antimicrobial resistance from food 
animals to humans. Four models (80, 89, 90, 113) included some reference to the 
environment, but not as a significant model component.  
Four models (39, 80, 88, 90) were reported to be system dynamics models of some kind, 
or exhibited some characteristics of an SD model. However, none of these would meet 
the criteria expected for the presentation of an SD model. Purposeful identification of 
feedback loops was particularly lacking. One of these models (80) was a quantitative 
system dynamics risk assessment model which used a DAG to illustrate the model 
qualitatively, which is at odds with SD goals of representing feedbacks in a system. The 
other two models were linear conceptual diagrams (89, 113). One of the models 
represented and discussed a feedback (113).   
Five of the six models (all but So et al., 2015) were policy oriented in some way; some 
aimed to assess the results of policy changes, some were aimed at eventually improving 
policy, and some included policy related variables. However, few specific policy 
inferences were drawn. The main policy statements were around the need to include non-
traditional stakeholders in AMR policy making (90) and to consider unintended 
consequences of policies that restrict use of antibiotics in food animals (80).  
None of the articles identified themselves specifically as One Health (though some 
discussed the importance of a One Health approach), and none mentioned EcoHealth. 
Two articles specified that model development involved participation of a group. 
However, one (Homer et al., 2000) did not specify what kind of ‘experts’ were involved 
in building the model and the other (Majowicz et al., 2018) relied on expertise within the 
author group.  
Overall the quality of the modelling studies was quite poor. Formal attempts at 
establishing and reporting model validity were generally lacking. Several models were 
reported to have used SD modelling methods, but did not meet several of the 





the papers, and therefore did not have much information given about them, which made 
quality and validity assessment difficult. Explicit assessment of model quality and 
validation was rare, which seems to be in keeping with the situation of systems-modelling 
techniques for public health research more broadly (28). 
Of the many articles written about antimicrobial resistance, an increasing number are 
calling for a systems approach to address the problem. However, most AMR models have 
tended to focus on a single domain (90) and the biological aspects of AMR (97). In 
investigating this area further, this literature review found very few models that integrate 
two or more of human, animal and environment AMR dimensions into a causal theory. 
None considered all three comprehensively. The environment dimension is particularly 
under-represented in the models found in this review, though it is increasingly recognised 
as an important reservoir of AMR.  
Despite the increasing literature on the need for integrative approaches to AMR, and 
recognition of AMR as the ‘quintessential’ One Heath issue (7 p.1), none of the models 
found in this review specified a One Health or EcoHealth approach. These are two 
holistic approaches to human, animal and environmental health that deserve more 
attention in AMR modelling. There is also lack of AMR models that are specific to 
particular countries or contexts. Whilst the models found in the review may be somewhat 
generalisable, policy options that work are likely to vary by context, as the main 
influences on AMR could vary by country. It would therefore be beneficial to have a 
New Zealand specific model of AMR.  
In this review, the most formal models were system dynamics models. This illustrates 
the potential usefulness of a system dynamics approach to modelling, which could be 
explored further.  However, there is room for improvement in this area in terms of 
expanding the scope of the models, and a need for better use of standard SD language 
and symbology. Explicit focus on feedback loops would be beneficial in helping identify 
and address the main drivers of the problem. In addition, models that balance the need 
for both simplicity and comprehensiveness are needed to provide confidence in model 





approaches to modelling appear to be under-utilised and could be built on in the area of 
AMR. Increased focus on validity of the models is also needed.  
3.4 Summary 
This literature review found very few studies that include causal model of AMR 
incorporating two or more of human, animal and environment dimensions. The small 
number of models found tended to focus on AMR transmission in the food chain. The 
most formal models tended to report using system dynamics modelling methods, but 
there is room for improvement in correctly applying SD principles and methods, as well 
as a need for models that consider quality and validity more explicitly. Participatory 
approaches were under-utilised. 
Based on these gaps in modelling efforts, I have chosen to build an integrated model of 
AMR in New Zealand using a participatory system dynamics approach, purposely 
underpinned by One Health and EcoHealth principles. Next, the methodology chapter 
will further describe and justify the suitability of such an approach to better understand 






4 Methodology chapter 
The previous chapters have outlined the complexity of antimicrobial resistance and 
identified the need for more integrative models of the problem. This chapter discusses 
the methodological principles that inform my research approach to better understand 
AMR in New Zealand. To begin this chapter, I explain my values and personal approach 
to research. Next, I discuss the One Health and EcoHealth research paradigms, which 
both inform this work. I particularly focus on how my project relates to the principles of 
EcoHealth, especially the principle of systems thinking. To conclude I focus on how a 
participatory system dynamics approach can operationalise these aforementioned 
theoretical underpinnings.  
4.1 Personal research approach 
I subscribe to the qualitative view that science occurs within a wider context and is 
influenced by the subjectivities of the researcher.  Thus, it is important that I am clear 
about the values and theories that inform my approach to this work, as this will influence 
the types of questions asked and how they are answered (114).  My background is in 
Medicine and Geography, and now Public Health. I have long-standing interests in both 
health and environmental issues, and the interconnections between them. These interests 
and areas of study have instilled strong values relating to environmental sustainability, 
equity, a holistic concept of health, and questioning of existing power structures. My 
definition of health is based on that of the World Health Organisation (1948): “a state of 
complete physical, mental, and social well-being and not merely the absence of disease 
or infirmity” (115 p.1) However, given the limitations of this definition (116), I extend 
my ideas about health to take into account the Ottawa Charter’s focus on enabling people 
to achieve their aspirations and cope with changing environments; the idea that health is 
a resource (115). Further, I take the public health position that individual health and well-
being is in large part determined by factors upstream (26), including social, economic 
and environmental dimensions (117).  
Ontology refers to our ideas about the nature of reality, whilst epistemology consists of 
ideas about how we know what we know (118). Positivist and constructivist paradigms 





(23, 119). Positivist ontology assumes that a single reality exists, and that scientific 
enquiry can be used to come to know this reality (23). Its epistemology assumes that 
scientific enquiry results in objective knowledge about that reality. On the other hand, 
constructivist positions contend that multiple, socially constructed realities exist (23). My 
position is that there is an external reality ‘out there’ (moderately positivist ontology (23)) 
but that it is important to understand the diverse subjective understandings of reality. 
Therefore, in terms of epistemology I lean more towards the ‘constructivist’ methods of 
building knowledge. I identify with the ‘critical realism’ theoretical position, which is a 
‘middle ground’ (120) that “accepts the existence of an external reality, but that it can 
only be known in subjective terms” (23 p.5)  
4.2 One Health and EcoHealth approaches 
This study is underpinned by One Health and EcoHealth research paradigms. Both 
incorporate holistic, systems-level conceptualisations of human health and its 
relationship with the health of animals and the environment, recognising the complexity 
of linkages between these three domains (21-24). They are two of several fields that 
operate at the interface between the health of ecosystems, humans and animals (24). An 
integration of these paradigms is shown in Figure 4.1 (overleaf). 
The smaller circles represent that the wellbeing of humans, domesticated animals and 
wildlife are closely overlapping. They are set within the context of human-created 
environments and human social, political and economic systems, which are embedded in 
and determined by the health of natural ecosystems (21, 117). Both EcoHealth and One 
Health approaches support using systems thinking for understanding and addressing 
health problems, and both value the integration of scientific disciplines through inter and 
trans-disciplinary research and collaboration (21, 22, 24, 121). However, their origins 
and focuses are different (23, 122). These holistic approaches to health are thought to be 
promising for dealing with ‘wicked problems’ such as climate change, food system 
problems, and built environment issues (122). The following sections will describe One 







Figure 4.1 One Health/EcoHealth integrating framework. Acknowledgments to 
Patricia Priest and Alex Macmillan 
 One Health 
One Health can be defined as collaboration between multiple disciplines at a range of 
scales to improve the health of people, animals and the environment (123). One Health 
addresses issues at the intersection of human, animal and environmental health (122). 
Biological threats are particularly referred to as needing a ‘One Health’ approach for 
prevention and mitigation (124). One Health research was historically health-science 
driven, and mainly focuses on the links between humans and animals (22), particularly 
addressing biomedical questions relating to zoonotic disease threats (21, 22). The main 
actors involved in One Health tend to be veterinarians and public health practitioners, 
though involvement of other disciplines is growing (22, 23). The role of the environment 
is increasingly considered, but not as habitually as in EcoHealth (23, 121). In practice, 
One Health tends to emphasize positivist aspects of veterinary and medical disciplines 
(23), but this is changing. 
The background chapter established that the complex issue of AMR has links to all three 
of the One Health domains. It is increasingly recognised that a ‘One Health’ approach to 
understanding AMR, that appreciates the complexity of interactions between human, 





countries and international agencies reflect this (21, 128).  New Zealand’s Action Plan 
on Antimicrobial resistance (129) was developed by an inter-disciplinary Working 
Group, evidencing an approach informed by One Health. 
In this research I have recognised AMR as a One Health issue by involving stakeholders 
from the three domains: human and animal health, and the environment. As will be 
outlined in the methods chapter, stakeholders were specifically selected to gain 
information about these three interconnected areas. As well as regarding One Health 
approaches as fundamental to tackling AMR, there is also recognition by some that 
involvement of economic and social sciences is also required (7). In this research I have 
used EcoHealth principles to help provide a complementary approach and further guide 
my methodological choice.  
 EcoHealth 
Many of the human health and environmental challenges facing the world today are 
interlinked, urgent, large-scale, multi-dimensional, complex, and uncertain (130). 
Integrative approaches are needed to overcome the limitations of traditional reductionist 
science in dealing with such complexity (25, 131). Ecosystem approaches to health seek 
to achieve this, and underpin my approach to this study. EcoHealth is an evolving field 
of research and practice (117) centred on understanding the reciprocity of relationships 
between human health and ecosystem health at a range of scales (22, 117, 120, 132). In 
essence, EcoHealth assumes that: “humans, and our social and economic systems, are 
embedded within ecosystems, and that these coupled social–ecological systems behave 
as complex systems” (25 p.19). 
The EcoHealth paradigm emerged in Canada in the 1990s as the need for new ways to 
address complex, persistent and inter-related health challenges was recognised (117, 
130). EcoHealth recognises that single-sector, non-participatory approaches and 
technological fixes are ill suited for dealing with these kinds of problems (130, 133). It 
adopts a broader conceptualisation of health than One Health, and has been strongly 
influenced by the sustainable development movement (122). Although animal health is 
included in its scope, it is not generally the focus (117). EcoHealth places more emphasis 





the value of local and Indigenous knowledges (134). It is common for EcoHealth research 
to proceed in an iterative way, involving knowledge generation, action and reflection 
(130). According to Albrecht (2008), EcoHealth is underpinned by the critical realism 
philosophy. EcoHealth’s transdisciplinary focus acknowledges the existence of multiple 
subjective socially constructed realties (23). It therefore suits my own research approach. 
The principles and spirit of the 1987 Brundtland report (135) – social justice, 
participation, and equity – strongly inform EcoHealth thinking and practice (122). 
EcoHealth seeks to improve human health while fostering thriving and resilient 
communities, alongside environmental sustainability (117, 130). Use of a range of 
integrative approaches and methodologies reflect the complexity of the public health 
issues being addressed, which is considered by some to be a significant advance in public 
health research (117). There is growing evidence of the effectiveness of EcoHealth 
approaches for addressing health challenges that are systemic, particularly when 
vulnerable populations are affected (117). It has often been focused on helping manage 
health and environmental issues in developing countries (130). 
Charron (2012) laid out a set of six widely cited ‘guide posts’ that inform EcoHealth 
research. The first three principles (systems thinking, transdisciplinarity and 
participation) relate to the ideal process of the research, whilst the other three 
(sustainability, gender and social equity, and knowledge-to-action) are more focused on 
the intrinsic goals of EcoHealth research (130). These are now discussed in more detail. 
1. Systems thinking: EcoHealth approaches seek to understand the complex, 
multidimensional relationships involved in human and ecosystem health (132), 
acknowledging that ecological, socio-cultural, economic and governance 
factors are involved (130). Fundamentally, systems thinking seeks to 
understand how things are connected to each other to form the whole (136). 
Systems thinking is a diverse field in its own right covering hard, soft and 
critical traditions (137). 
 
2. Transdisciplinarity: EcoHealth approaches recognise that academic 





social-ecological systems (130), and that development of  “socially robust” 
(133 p.11) solutions requires integration of different scientific disciplines 
(inter-disciplinary) and non-scientific perspectives, such as community, policy 
and industry perspectives (132, 138). This necessitates engagement of 
researchers with community members and decision-makers, including people 
with informal influence due to their knowledge, experience and reputation 
(130, 133).  
 
3. Participation: Related to the concept of transdisciplinarity, participation 
further emphasises the value of developing a shared understanding of 
problematic situations and locally rooted solutions, aiming for cooperation 
within and between groups and improved appreciation of alternate worldviews 
(130, 133, 139). EcoHealth projects should consider local knowledge, concerns 
and needs (133). Engagement of stakeholders increases the likelihood of 
gaining new insights and successfully implementing context-appropriate 
solutions (130, 133).  
 
4. Sustainability: Given that EcoHealth is based on the assumption that 
ecosystem health  is a fundamental requirement for current and future human-
wellbeing, it posits that changes resulting from research ideally should be both 
environmentally and socially sustainable (130). 
 
5. Gender and social equity: EcoHealth considers unfair impacts on 
disadvantaged groups in societies (130) and is oriented towards reducing 
inequities (132). However, Charron (2012) acknowledges that truly addressing 
inequity, rather than simply commenting on it, is difficult.  
 
6. Knowledge-to-action: Knowledge generated in the iterative process of 
EcoHealth research is aimed at achieving real-world change that creates better 
environments for supporting human health (130). That is, the application of 
knowledge is very important. ‘Research-action cycles’ acknowledge the need 





The principle of systems thinking is particularly prominent in my research, so will be 
elaborated on next. 
4.3 Systems thinking 
As highlighted by EcoHealth approaches, in a world that is highly interconnected and 
rapidly changing, integrated approaches to dealing with complex problems are needed 
(25, 123). Many public health challenges are complex dynamic problems (27, 136), 
characterised by multiple interacting variables, diverse values and concerns of people 
involved, changing contexts, and changing patterns over time (26, 136). Systems thinking 
is an approach to problem solving (140) that views the world as a complex system (107) 
and considers how things are connected within the broader ‘whole’ (136, 141). In systems 
that give rise to complex problems, actors such as policy makers, providers, organisations 
and communities interact in dynamic and sometimes unpredictable ways (27). Dynamic 
systems consist of interconnected material and immaterial elements, which change 
throughout time and exhibit patterns such as growth, decline, oscillation and overshoot 
(140, 142).  
 
Systems thinking has origins in a variety of disciplines, as diverse as: biology, 
anthropology, physics, psychology, mathematics, management and computer science 
(136). As a result, there are many theories, methodologies, methods and tools covered by 
the field of systems thinking (26, 136). Some examples of systems thinking methods and 
tools include complex adaptive systems, system dynamics, agent-based modelling, 
network analysis, discrete-event modelling and cybernetics (27, 143). Like EcoHealth, 
systems thinking approaches often feature inter-disciplinary and multi-disciplinary work, 
including involvement of the social sciences (107, 136, 144). Systems thinking aims to 
support shared decision making (141), often by explicit inclusion of stakeholder groups 
affected by the research alongside the researchers (transdisciplinarity) (136, 141). Some 
systems methodologies involve the building of quantitative models that allow simulation, 
whilst other approaches are more qualitative and action-based (28).  
Although there are perhaps more than 1,000 methods and methodologies in the systems 
field, “making sense of inter-relationships” (141 p.34) is a foundational concept for all 





individual components themselves (140, 142, 145) – a contrast with traditional 
reductionist approaches that seek to understand individual components in detail (27). 
Systems thinking explores how things are connected, and the effect of these causal links 
(145). These interactions are often complex and non-linear in nature (146). Other 
important concepts include recognition of the diversity of perspectives different people 
hold regarding a system, and the impact of  value judgements and power dynamics in 
how issues (and their possible solutions) are framed (145). Systems science methods are 
useful for considering nonlinear relationships, unintended effects of interventions, and 
time delays (143). Table 4.1 illustrates some of the differences between the classical 
approach to problem solving and the systems thinking approach (140). 
 
Table 4.1 Classical versus systems thinking approaches to problem solving (Adam and 
de Savigny, 2012)2  
Classical approach Systems thinking approach 
Static thinking 
Focusing on particular events 
Dynamic thinking 
Framing a problem in terms of a pattern of 
behaviour over time 
System-as-effect thinking 
Viewing behaviour generated by a system as 
driven by external factors 
System-as-cause thinking 
Placing responsibility for a behaviour on 
internal actors who manage the policies and 
‘plumbing’ of the system 
Tree-by-tree thinking 
Believing that really knowing something 
means focusing on the details 
Forest thinking 
Believing that to know something requires 
understanding the context of relationships 
Factors thinking 
Listing factors that influence or correlate with 
some result 
Operational thinking 
Concentrating on causality and understanding 
how a behaviour is generated 
Straight-line thinking 
Viewing causality as running in one direction, 
ignoring (either deliberately or not) the 
interdependence and interaction between and 
among the causes 
Loop thinking 
Viewing causality as an on-going process, not 
a one-time event, with effect feedback back to 
influence the causes and the causes affecting 
each other 
Source: Adam and de Savigny (2012), modified from Richmond (2000) 
                                                 
2 Reproduced from Adam and de Savigny, ‘Systems thinking for strengthening health systems in LMICs: 
need for a paradigm shift’, Health Policy and Planning, 2012, Issue suppl_4, p. iv1-iv3, by permission of 





Systems thinking offers an approach improving decision making in complex contexts 
(147). Donella Meadows, a pioneering systems thinker, wrote: 
 
“Once we see the relationship between structure and behaviour, 
we can begin to understand how systems work, what makes them 
produce poor results, and how to shift them into better behaviour 
patterns”(148 p.1).  
Systems approaches have been particularly popular for natural resource management and 
addressing unsustainable consumption since the publication of the seminal work The 
Limits to Growth (149) in 1972 (31, 141). Systems science approaches are said to hold 
great potential for dealing with the dynamic complexity of many public health and health 
system issues (122, 136, 140, 143, 144, 146, 150). Examples of situations where systems 
science has been applied to public health include simulation modelling of Type 2 diabetes 
(151), assessment of the effectiveness of policies aimed at reducing smoking prevalence 
(152), and demonstration of how a focus on curative medicine crowds out prevention 
(153). A 2015 systematic review of the  applicability of systems thinking to public health 
found many articles that discuss the potential of systems science, but fewer described 
how this could be implemented (28). The review found 36 papers that described systems 
modelling examples of relevance to public health, of diverse quality (28). 
 
It has been observed that many public health interventions fail to achieve their goals 
because they are made using compartmentalised, reductionist approaches rather than 
comprehensive, interdisciplinary, whole-system perspectives (27, 136, 140, 150). 
Seemingly-obvious policies that seek to improve public health and human welfare often 
fail, or paradoxically worsen the problems they aim to address (a phenomenon called 
‘policy resistance’) (107, 143, 147). For example, the use of antibiotics to treat infections 
has accelerated development of AMR, which undermines our ability to deal with 
communicable disease (147). A number of factors may contribute to policy resistance, 
including poor understanding of the system and narrow conceptualisations of cause and 
effect (107). As our actions alter the state of the system, other actors may react to restore 





Systems thinking generally involves the creation of a model – a compact representation 
of how a phenomenon or system is understood (136). Models have a variety of uses 
beyond the commonly-considered purpose of ‘prediction’ (154). According to Epstein 
(2008), some of these include: explaining how things work, testing of policy 
interventions, identification of areas where more data is required, raising new questions, 
making assumptions explicit, testing hypotheses, and calibration against real data (136, 
154). Systems thinking aims to create models that provide a robust and useful perspective 
on the inner workings of complex problems. Simulation modelling in particular may hold 
high potential for improving health (91).  Advanced system models that allow simulation 
can help identify important leverage points where interventions are most likely to have 
the greatest impact (28, 144, 155), and allow designing and testing of policies in a way 
that is safe and inexpensive (107, 136, 156). 
 Participatory system dynamics 
System dynamics (SD) modelling is a systems thinking methodology that particularly 
highlights the principle of inter-relationships (157) and has been identified as a suitable 
approach for dealing with and addressing the dynamic complexity that characterises 
many public health issues (150). Of the AMR models discussed in the literature review, 
those featuring system dynamics models were most common, and represent work that 
can be built on further. In addition, system dynamics is particularly useful for identifying 
feedback loops that govern problems, and helping to identify high-leverage policies that 
can make helpful lasting change (107, 150). SD modelling processes involve developing 
causal diagrams and policy-oriented simulation models, so that alternative policies and 
scenarios can be tested systematically (150, 158). 
As with the wider field of systems thinking, SD is useful in situations of dynamic 
complexity: where there are delays between causes and effects, actors in systems have 
multiple goals and interests that may conflict with each other, and interventions can have 
unintended consequences (150). System dynamics modelling has therefore been 
identified as a suitable approach for dealing with and addressing the dynamic complexity 
that characterises many public health issues (150). There is increasing literature 
promoting the value of SD modelling to aid policy making, but its practical application 





population health (150), with success in addressing epidemiological issues, health care 
capacity and delivery, and patient flow management (150), as well as HIV and diabetes 
(107). It has also been applied to topics such as commuting modes (108), tobacco control 
(144) and obesity (160, 161). There are examples of studies using SD for public health 
policy or healthcare policy (159) for health topics including smoking cessation (162), 
disease screening (163), mental health issues (164), and pharmacotherapy treatment for 
opioid dependence (165).  
 
The theoretical assumptions of system dynamics modelling may make it a useful way of 
converging One Health and EcoHealth, as: “its critical realism underpinnings offer users 
a means of reconciling the belief in an external reality and the subjective nature of 
knowledge” (23 p.2). SD suits my appreciation for both quantitative and qualitative 
methods. It aligns with my belief that health, equity and sustainability are intricately 
connected, and that taking well-considered action to improve one can have co-benefits 
for the others, while reducing negative unintended consequences. It allows me to occupy 
‘the middle ground’ on the spectrum between positivist and constructivist leanings, 
seeing value in both. System dynamics is a particularly appealing type of systems science 
because it can be suitably employed for participatory model building (159). 
System dynamics has long recognised the value of modelling with ‘problem owners’ 
(166); inclusion of multiple perspectives improves the quality of decision making and is 
more democratic (167). Participation in system dynamics historically tended to involve 
inclusion of clients in business modelling efforts (166, 168), and was thus fairly 
technocratic. However, it has also been used to support better democratic decision-
making,  including fostering shared understanding and consensus on management of 
complex environmental issues (31, 104, 166, 169-171), such as water resources planning 
(172). In more public health specific applications, pSD has been used to assess the 
interactions between housing, energy and wellbeing (158, 173), reducing alcohol-related 
harm (174), cardiovascular disease prevention (175), and emergency care (163). 
Stakeholder involvement in modelling processes improves the richness of models, fosters 
social learning and consensus, and builds ownership of the model and commitment to the 





Participatory modelling has been proposed as a useful tool for enabling One Health 
integration of stakeholders in practice (20). Further, it has been recommended for 
operationalising the principle of systems thinking that is common to both One Health and 
EcoHealth (30). In order to deal with complexity, integrated approaches to health (such 
as One Health and EcoHealth) need to be iterative, adaptive and participatory, and 
participatory modelling provides a practical way for meeting these requirements (30). 
Participatory modelling is transdisciplinary and facilitates knowledge sharing, 
knowledge generation, negotiation and planning (30), by allowing integration of various 
types of information (31). The process of model building helps stakeholders to clarify 
their own mental models of the problem, appreciate the perspectives of others, and build 
an enhanced understanding of the system (31). In other words, participatory modelling 
enables me to operationalise some of the key principles of EcoHealth (participation, 
transdisciplinarity and systems thinking) in this research. 
A classic ‘heuristic’ of participatory system dynamics (pSD) modelling involves an 
iterative process of developing a qualitative understanding of a system (involving the 
development of a causal loop diagram, described in section 5.2.1), followed by 
conversion to a quantitative model, incorporating data and allowing simulation. This 
improves the causal theory and facilitates understanding of the impacts of policy 
decisions. Performing the whole process was out of scope for this thesis. I therefore set 
the foundations for a participatory system dynamics approach by establishing a diverse 
stakeholder group and developing a preliminary set of causal loop diagrams.  
4.4 Summary 
This research is underpinned by One Health and EcoHealth, two integrated approaches 
to health that recognise the value of systems thinking and transdisciplinary work. 
Participatory system dynamics modelling, my chosen method, sits well with the values 
of these underpinning approaches and has been suggested as a useful way to 
operationalise systems thinking and One Health in practice. The next chapter describes 
the methods used to build a qualitative system dynamics model of antimicrobial 






This project used a participatory system dynamics approach to develop a qualitative 
model of AMR in New Zealand, building on AMR science, policy, community, clinical 
and industry knowledge. It aimed to identify feedback loops that drive the behaviour of 
the system. The project was participatory in that interviews with diverse stakeholders 
with expertise about AMR provided the basis for identifying variables in the model and 
the relationships between them. In this chapter I describe the participatory system 
dynamics (pSD) process and explain causal loop diagrams and cognitive mapping. I then 
outline the process for stakeholder selection and recruitment, data collection (interviews) 
and data analysis (cognitive maps, thematic analysis, and development of causal loop 
diagrams). Ethical aspects of the project are discussed at the end of the chapter.  
5.1 Participatory system dynamics process 
According to Sterman (2000), active participation of decision makers in the development 
of a model is essential for effective learning to occur (107). Addressing public policy 
problems generally requires consensus, or at least accommodation (139), among diverse 
stakeholders, so group model building processes are a key part of SD methods (150). I 
am building the foundations for a participatory approach by identifying and recruiting 
transdisciplinary stakeholders and taking the first steps to elicit their individual mental 
models. Participatory system dynamics modelling generally involves three stages (Figure 
5.1)3: preparatory activities, modelling workshops, and follow-up activities (166). In this 
research I complete stage one (preparatory activities), which constitutes an analysis of 
stakeholders who should be invited to take part, and a preliminary assessment of 
stakeholder perceptions of the problem (166). Interviews with stakeholders are useful for 
building rapport with participants and for building a preliminary SD model (166).  The 
qualitative CLDs are a crucial first step in the model building process. The next steps 
would involve participatory workshops and development of a quantitative model for 
simulation.  
 
                                                 
3 Reprinted/adapted by permission from Springer Nature: Springer International Publishing, 





An initial step in building a participatory SD model is to synthesise qualitative 
impressions from the stakeholders about problem trends over time, and hopes and fears 
for the future. This qualitative impression is generally in graphical form, and is called a 
reference mode (107 p.90). Reference modes show trends such as exponential increase 
or decay, S-shaped growth, and oscillations (176). They may also illustrate possible 
future trends after a policy is carried out (176). Formulating the reference mode is an 
important part of the problem ‘conceptualisation’ stage of SD modelling (176). Reference 
modes can be referred to throughout the modelling process (107), as well as being useful 
for checking model plausibility (176). In the interviews I asked questions about AMR 
trends over time and best and worst case scenario projections to help develop a reference 
mode for AMR in New Zealand. 
Figure 5.1 A generic participatory system dynamics modelling process - main stages 





5.2 Model explanations  
In this section I describe what causal loop diagrams are and how to read them. 
Development of causal loop diagrams that synthesise feedback loops involved in AMR 
in New Zealand was a key goal of this research. I also discuss cognitive mapping, which 
was an intermediary step in the development of the CLDs. The fundamental principle of 
system dynamics (SD) is that the structure of a system gives rise to its behaviour over 
time (107, 177). Key concepts involved in SD modelling are feedback processes, stocks, 
flows, time delays and non-linearities, which together determine the dynamics of a 
system (107). Feedback loops are chains of cause and effect relationships that link into 
loops (142), and are recognised as the main source of complexity and determinants of 
dynamics in a system (107, 150). These feedbacks may be positive (self-reinforcing 
loops) or negative (self-correcting/balancing loops) (107). In this research, the ultimate 
product is a causal loop diagram (CLD) model that displays such feedbacks. 
 Causal loop diagrams 
CLDs are a commonly used starting point in the system dynamics tradition (136, 158) 
for qualitatively representing the causal structure of a dynamic system (178). They are 
based on system dynamics principles and are widely used for systems visualisation and 
communication (141). CLDs are useful for helping groups of people come to a common 
understanding of an issue, by incorporating a variety of perspectives on how elements of 
a problem are related to each other (136). Causal loop diagrams are developed by eliciting 
and representing people’s mental models about how one thing causes another, and the 
nature of these relationships (136).  Feedback loops between variables can then be sought 
(136, 177, 179). Causal loop diagrams can later be converted into quantitative system 
dynamics models called stock and flow models, with equations used to describe the 
relationships between variables. The quantitative and simulation aspects are beyond the 
scope of this thesis.  
Causal loop diagrams (CLDs) are widely used in system dynamics. Such diagrams can 
be used to represent a set of causal assumptions, and are a valuable communication tool 
that can then be discussed and debated with stakeholders to develop a shared 
understanding of issues (177).  Causal loop diagrams aim to show the key aspects of 





connected by arrows, which represent causal links. The arrows have polarities associated 
with them (+ or – signs) to indicate the type of relationship. A positive sign means that a 
change in the independent variable causes a change in the dependent variable in the same 
direction, whilst a negative sign represents that changes occur in the opposite direction 
(178). Variables are connected in loops that form circles of cause and effect. Small 
parallel lines (delay marks) may be added to arrows (see Figure 5.2) to represent links 
that have significant time delays.  
The interplay and relative strength of different loops in a system will drive its behaviour 
(107). If we can identify these, there is potential to be able to take action to produce a 
desired result while avoiding unintended consequences. Positive (reinforcing) loops 
reinforce or amplify a process such that a change in any element involved in the loop will 
cause a cascade of changes that result in the original element changing even further in 
the same direction (107, 142). Reinforcing loops have the potential to generate 
exponential (runaway) growth in a system (142). In contrast, negative (balancing) loops 
counteract and oppose change (107), and tend to regulate growth (142). Reinforcing 
loops have either an even number of (-) arrows, or only (+) relationships. Balancing loops 
contain an odd number of (-) relationships (181). Figure 5.2 shows a simple example of 
a reinforcing and balancing loop (181).  
This example shows that as population size increases, eventually this will increase the 
number of births, further adding to the population (reinforcing loop, R). A reinforcing 
loop operating on its own could lead to exponential growth in the size of the population. 
However, as population increases, this eventually results in an increased number of 
deaths, limiting population size (balancing loop, B). The balance of these loops (and 
probably others) will determine the size of the population.  





CLDs are useful for representing feedbacks and interdependencies, but a limitation is that 
they do not represent the stock and flow structure of systems (107). Stocks are 
accumulations (such as the quantity of water in a bath-tub) with inflows and outflows, 
and are fundamental to generating the dynamic behaviour of a system (107). Further steps 
in an SD modelling process would convert CLDs into a stock and flow format to allow 
quantitative modelling. 
 Cognitive maps 
An intermediary step in developing these causal loop diagrams was drawing cognitive 
maps from each interview. Cognitive maps represent a person’s thinking about a problem 
or issue, and consist of nodes linked by arrows that imply causality (182). Cognitive maps 
can be described as ‘mental models’. Cognitive mapping is a formal modelling technique 
that is usually applied during interviews (182), that can be used as a basis for problem 
structuring to build a system dynamics model (179). These diagrams portray how people 
make sense of a problem, displaying their understanding of how a situation has developed 
and why it is problematic (179). It therefore is informed by the values and beliefs of the 
problem structurer (179). Cognitive maps may directly or indirectly imply an 
understanding of what can or cannot be done to address the problem (179).  
Cognitive mapping is a useful tool for acknowledging the richness and complexity of 
multiple perspectives, and for identifying feedback loops (179). Such causal maps help 
show the causes and consequences of ideas or actions, and making sense of complex 
problems with a large number of ideas and interconnections (183). The direction of 
arrows in cognitive maps implies believed causality – the statement at the tail of an arrow 
is thought to influence, or cause, the statement at the arrowhead (182). Concepts are 
linked and related to each other to form a hierarchy of means and ends (184).  Where 
possible, contrasting poles are included for a concept (bipolar constructs) (179).  
5.3 Stakeholder selection and recruitment process 
Robinson (2014) has proposed four useful theoretical and practical concerns for 






Table 5.1 Theoretical and practical concerns for sampling in qualitative research 
(Robinson, 2014) 
 Name Definition Key decisional issues 
Point 1 Define a sample 
universe 
Establish a sample universe, 
specifically by way of a set 




and exclusion criteria 
Point 2 Decide on a sample 
size 
Choose a sample size or 
sample size range, by taking 
into account what is ideal 
and what is practical 
Idiographic (small) vs. 
nomothetic (large) 
Point 3 Devise a sample 
strategy 
Select a purposive sampling 
strategy to specify categories 
of person to be included in 
the sample 
Stratified, cell, quota, 
theoretical strategies 
Point 4 Source the sample Recruit participants from the 
target population 




To define the sample universe, we established inclusion criteria for the study. To be 
considered for inclusion, people had to be an expert in human, animal and/or 
environmental health with respect to AMR, and be in a position to understand and/or 
influence policy. Their work had to have a strong focus on AMR. These fairly broad 
inclusion criteria allowed for heterogeneity in the sample universe, which helps ensure 
findings are more widely generalisable (185). This is desirable for development of a 
shared causal theory. 
There is no definitive guidance on the optimal group size for participatory modelling 
(104). However, it is clear there are situation dependent trade-offs that must be made 
(186): increased number and diversity of participants may increase the usefulness of the 
resulting model (187), yet on the other hand, larger groups can result in reduced 
communication between participants and increased likelihood of a few people 
dominating the conversation (188, 189), especially if there are conflicting interests (187). 
Richardson and Andersen (1995) prefer a group size of 12, though up to 25 is possible. 
Van den Belt (2004) prefers involvement of 20-30 participants. A minimum of 5-10 
participants has been recommended to allow for creativity and a broad knowledge base 





the wide range of important perspectives that an issue as complex as AMR is likely to 
generate, whilst accounting for the time and resource constraints of this Masters project.  
A purposive sampling strategy was chosen to identify potential people to invite to take 
part. A non-random approach to sampling ensures particular types of people with unique 
or important perspectives can be represented in the sample.  Based on our understanding 
of the range of actors involved in or affected by AMR, we developed an a-priori sampling 
framework that would target the dimensions of human, animal and environmental health. 
These are addressed by different types of stakeholders (academic/research, policy, 
community, industry and clinical) (Table 5.2).  A similar Kaupapa Māori project about 
AMR is operating in parallel, so specific Māori representation was not a requirement for 
this project. The parallel project is led by a Māori Masters student and their supervisors. 
Table 5.2 A-priori sampling framework 
Some of the cells in the above sampling framework have multiple important sub-areas 
which were already well known. Hence it was expected that participation in the project 
would be skewed towards some of these cells (such as human clinical). For other cells, it 
was expected that it could be difficult to find a suitable representative. There was some 
debate about whether to include industry groups in the process, as within current 
economic and legislative environments, the job of business is to maximise stakeholder 
returns. This can often be incommensurate with public health goals (190). However, we 
decided industry would be likely to have important insights into the issue that would be 
valuable to include, at least at this initial stage of the participatory modelling process. 
Also, the aim of the qualitative model is initially to represent a variety of stakeholder’s 
views/understandings of AMR, including areas of disagreement.  
 Human Animal Environment 
Academic/Research     
Policy    
Community    
Industry    





Initial ideas for particular individuals or groups to approach came from supervisory 
knowledge of those in the field, asking others knowledgeable about AMR, and from 
looking at the list of organisations involved in the AMR working group. This is a 
multidisciplinary group that gave a good indication of the types of experts active in AMR 
policy. We also considered ideas for more ‘non-traditional’ stakeholders who could be 
valuable to talk to from the Canadian system dynamics modelling paper described in the 
systematised review (90). This process generated an initial list of groups/individuals to 
approach. 
To source the sample, emails of invitation were sent out to the individuals/organisations 
previously identified. Where I was uncertain who was most appropriate to contact, query 
emails or phone calls to people in the organisation who seemed likely to know helped 
start the process. In some cases snowball sampling aided recruitment (chain sampling); 
people I approached sometimes referred me to others who would be better placed to help. 
I also specifically asked people I interviewed for recommendations of who else would be 
good to talk to. These ‘referral chains’ (185) helped find more participants and also to 
confirm that the people I interviewed were considered by others to be important to talk 
to. In one case I used an advertising approach to recruit – after being in contact with 
several environmental organisations and not finding any working on AMR, I put a small 
advertisement in the newsletter of an umbrella environmental group.  
Potential participants were sent an email and information sheet describing the study and 
asking them to consider taking part. If there was no response within 1-2 weeks, a follow 
up email was sent or a phone call made. If interest was expressed, a consent form was 
sent for their consideration. If they were happy with the consent form, I liaised with them 
to organise an in-person interview. Copies of the information sheet and consent form are 
in Appendix C and D.  
5.4 Data collection process 
 Semi-structured interviews 
Face to face interviews were arranged at a time and place convenient for the participants. 





same organisation and/or expressed a preference to be interviewed together. To begin the 
in-depth semi-structured interviews (191) I re-iterated the purpose of the study and 
participants completed the consent form. I also requested permission to audio-record the 
interviews for the purposes of transcribing. Semi-structured interviews allow a focus on 
key questions with the opportunity to discuss particular areas of interest – they give the 
interviewer the option to explore answers in more depth (192), which is ideal for drawing 
out interviewee mental models and developing cognitive maps. 
The focus of the interview was to explore interviewee’s ideas about the main causes and 
effects of AMR in New Zealand, to support the development of the CLDs. Therefore, the 
main questions were about interviewee’s opinions on the main causes and effects of 
AMR.  During each interview I used a pencil and paper to draw out suggested 
relationships between variables interviewees discussed. A range of prompting questions 
were designed to support the development of the maps. If long ‘lists’ of  ideas were 
offered, these were noted down and returned to in more detail one by one (as 
recommended by Bryson et al., 2004). Proximal and distal drivers and consequences 
were explored with the aid of prompting questions such as ‘what might be 
driving/underlying/causing that?’ and ‘what might be the effect/consequence/result of 
that?’ and ‘how might that relate to…?’  This can be described as “laddering up and 
down the chains of argument” (183 p.187). A copy of the semi-structured interview sheet 
can be found in Appendix E. I tried to avoid leading questions that would prompt the 
interviewees to talk about particular themes, as it is preferable that they spontaneously 
discuss their ideas. During the interview I took notes and drew preliminary cognitive 
maps. These cognitive maps were then completed in more detail upon transcribing the 
interviews. 
Other specific questions were asked to build rapport and understanding of stakeholder 
roles, develop an understanding of participant perceptions of AMR trends, and to 
specifically target questions of equity. These questions were: 
1. How their job relates to AMR. 
2.  Why they think AMR is important/why they are interested in it. 
3.  AMR trends – how they think it has changed over time, e.g. 





4.  Projections for future trends: what might happen if we continue business 
as usual, or without good policy intervention, versus what could be the 
best we could hope for if effective action is taken to tackle the problem 
(fears and hopes). These questions also helped add to the reference mode. 
5. How equity issues might be involved in the issue of AMR. 
6.  Top policy (or high-level actions) recommendations to reduce AMR in 
New Zealand. 
 
5.5 Data analysis process 
Thematic analysis and development of causal loop diagrams (via the cognitive mapping 
step) proceeded simultaneously. Thematic analysis is a method for identifying, analysing 
and reporting patterns (themes) within data (193). It is important to make clear the 
methods used for thematic analysis, and the assumptions that informed the analysis (193). 
Thematic analysis was a recursive and iterative process, which was informed by the 
process of cognitive mapping. Identification of themes is an active process (193), and in 
this case coding was directed by searching for ideas about determinants and effects of 
antimicrobial resistance. I did not focus on the exact number of times a theme was 
discussed, as this does not necessarily reflect its importance (193). The aim was to 
synthesise a rich account of the entire dataset rather than to elaborate on very detailed 
aspects of a particular theme. I carried out a targeted deductive thematic analysis by 
searching for instances where causes and consequences of AMR were discussed. The 
process of thematic analysis followed the six steps outlined by Braun and Clarke (2006): 
familiarizing yourself with your data, generating initial codes, searching for themes, 
reviewing themes, defining and naming themes, and producing the report.  
Listening to the audio recordings and transcribing the interviews was an important first 
step in familiarizing myself with the data. All the interviews were transcribed ‘intelligent 
verbatim’ so ums, ahs, repetitions and false starts were removed, except in cases where 
they indicated genuine uncertainty or hesitancy, as full verbatim would not add value for 
the purposes of SD modelling and thematic analysis. Transcribing assistance was 
provided for some of the interviews by a research assistant and a transcription company 
(approved by the Ethics Committee). I double checked all transcripts for accuracy and 





transcript and adjusting as appropriate. Completed transcripts were emailed to the 
interviewees for optional checking and approval. No response after two weeks of sending 
the transcripts was taken as approval. Listening to and transcribing the interviews helped 
me to start thinking about patterns and interesting aspects of the data. 
Generating initial codes was pursued through the process of drawing complete cognitive 
maps for each interview. During the interviews and when finalising the cognitive maps, 
I had to make decisions about when to start a new cognitive mapping section or page. 
These decisions therefore represented a first step in the thematic analysis. Completed 
cognitive maps were sent to interviewees to review. This gave them the opportunity to 
check their ideas were represented accurately, and to make clarifications/additions.  Once 
all cognitive maps were completed and approved, initial ideas of codes were further 
clarified by labelling maps or parts of maps as different types of causes and effects of 
AMR. For example: ‘pharmaceutical economics and antibiotic development’ and 
‘chemical co-selection for resistance’ and ‘drivers of prescription in humans’.  
The next stage identified by Braun and Clarke (2006) in the process of thematic analysis 
is ‘searching for themes.’ Following discussion with the project supervisory team and 
consideration of the codes identified from the interviews, five overarching themes 
relating to participants ideas about the causes and effects of AMR in New Zealand were 
identified. The codes were organised as sub-themes under these headings. During stage 
four, ‘reviewing themes’, I re-organised some of the sub-themes as I reflected on how 
they would best fit together. NVivo 11 (a computer program for qualitative analysis)4 
was used to help collate the cognitive mapping diagrams from the interviews and to track 
sub-themes.  
Stage five of ‘naming and defining themes’ involved further work to better name and 
define each theme and the subthemes within it. Stage six ‘producing the report’ can also 
be considered part of the process of thematic analysis, as I revised my ideas about what 
                                                 





was most important to include. The process of writing helped to further clarify and order 
subthemes. 
 Development of the CLDs 
Following refinement of the themes and subthemes, I was ready to develop causal loop 
diagrams based on the thematic analysis and the cognitive maps. The CLDs were drawn 
using Vensim PLE computer software (194). Vensim is a recommended package for 
system dynamics (180). I considered all the relevant cognitive maps associated with each 
subtheme and focused on identifying feedback loops. This included loops that individual 
interviewees identified, as well as connecting ideas from different interviewees to form 
loops. The nature of each loop (balancing or reinforcing) was identified by working 
hypothetically around the variables involved in the loop to establish how a change in an 
initial variable would feedback to influence itself. Preliminary CLDs were constructed 
for all subthemes that had feedbacks identified. Discussion and reflection with the 
supervisory team helped to refine and clarify the feedback loops, as well as confirming 
the logic and cohesion of the loops. 
In cases where we postulated links that were likely to play a role based on our shared 
understanding of both AMR and system dynamics modelling, but were not specifically 
proposed in the interviews, causal arrows are shown in red. Consideration of the feedback 
loops identified in the literature review also helped to add detail; in cases where loops 
from the literature review were not reflected in the interviews, the arrows are green. In 
summary, the development of the CLDs triangulated the cognitive maps from the 
interviews, ideas from my background reading and understandings about AMR, what 
was learnt from the literature review, and the AMR and system dynamics expertise of the 
supervisors. The final step was combining the CLDs for the separate subtheme into an 
overall model that showed connections between the themes.  
5.6 Assessing validity 
As discussed in the literature review model, assessing the validity of a system dynamics 
model is a continual process of building confidence in the structure and utility of the 
model. Given that the CLDs developed here are a preliminary qualitative model, no 





about the model was ensured by giving participants the opportunity to check their 
interview transcripts and to approve the cognitive maps drawn from them. This helped to 
ensure that their main ideas about AMR were represented accurately. Working through 
the model with the supervision team also helped confirm the logic of the feedback loops, 
further building confidence in the accuracy and usefulness of the models. The model was 
also triangulated with previous system dynamics modelling efforts identified in the 
literature review. 
5.7 Ethics 
Ethics approval for this project was obtained from the University of Otago Human Ethics 
Committee (Category B) prior to commencing recruitment. No financial incentives were 
offered for participation in the research, unless the nature of the interviewees’ job meant 
they required payment for their time. A small food gift was offered as thanks after the 
interview. Care was taken to avoid disclosing interviewee identities unless they had 
consented to being named in the research. In the consent form interviewees were given 
the option of being acknowledged as a named individual contributor, having their 
organisation listed as a contributor, or neither, in any written reporting.  When using 
quotes in this thesis, care has been taken to minimise the likelihood of attribution to 
individuals. 
5.8 Summary 
This chapter has described the methods for participatory system dynamics modelling and 
outlined the process involved for this research. I have described the selection of 
stakeholders, interview process, and data analysis steps in the thematic analysis and 
causal loop diagram development. The next two chapters describe the results of this 
research. In Chapter Six I describe the participants who participated in the interviews, 
and discuss the results of the thematic analysis. Chapter Seven describes the reference 







6 Results: Interviews and thematic analysis 
The previous chapters have outlined the reasons for choosing a participatory system 
dynamics approach to address AMR, and detailed the methods used to achieve this. In 
this first results chapter, I outline the characteristics of the participants who participated 
in the research, then describe the main themes and subthemes that were synthesised from 
the thematic analysis. 
6.1 Interviewees 
Thirty-one people participated in in-depth, semi-structured interviews. In four instances 
two people were interviewed together, making a total of 27 interviews. Twenty-six 
interviews were conducted in person, and one via Skype (due to time and resource 
constraints). Interviewees were experts in AMR or their job roles meant they had 
important insights into the issue. Table 6.1 shows the types of job roles or organisations 
they came from, and how they fit into the sampling frame. Italics have been used to 
indicate when participants also had a second area of expertise relevant to AMR. For 
example, the Infectious Disease Physician was contacted primarily for their clinical view 
of the problem, but they also had a strong research background on the subject (and 
therefore are included in italics in the research box of the sampling frame). The 
interviewees held a broad range of expertise across human and animal health and 
environment sectors. Most interviews were about an hour in length, but ranged from 









Table 6.1 General job roles or organisations of interviewees 
 Human Animal Environment 
Academic/research  -Microbiologist, 
Institute of 
Environmental 






















Policy -Ministry of Health 
-PHARMAC 





-Rural vet (livestock) 
-Politician 
Community  -Consumer advisor 
 
Federated Farmers  




















Animal Health and 
Crop Protection 
(AGCARM) 
Clinical -Infection Prevention 












environmental fate of 
antibiotics 












                                                 






The distribution of participants was skewed towards certain boxes of the sampling frame, 
such as ‘human clinical’. There are many different clinical roles relevant to AMR, and it 
was important that the included participants reflected this. The environment dimension 
is weighted towards academics because it was difficult to find participants who 
represented other role types. We were unable to find a community environmental group 
that was involved in creating AMR policy or advocating on environmental aspects of 
AMR. Several of the interviewees held senior leadership positions within their 
organisations, and many are involved in the AMR Action Group (an inter-disciplinary 
group that has designed New Zealand’s Action Plan on AMR). In this sense they are in 
a strong position to influence AMR policy. When quotes from the interview are used for 
illustration in the thematic analysis, the interview number and main job role are given (P 
= policy, A = academia, CL = clinical, CO = community, I = industry). This is to be 
transparent about ensuring a wide variety of voices are represented by the quotes.  
The names and organisations of those involved are listed in the acknowledgments. 
Twenty-five people gave consent for their names to be acknowledged, and six preferred 
to have only their organisation listed.  
6.2 Results of the thematic analysis 
The cognitive mapping process resulted in 114 A3 pages of cognitive maps, with between 
two and 10 pages of maps associated with each interview. It should be noted that the 
number of maps on each page varied depending on how extensively an idea was talked 
about (and therefore how much space a map occupied). Examples of some cognitive 
maps from the interviews, alongside more detail about how to read them, can be found 
in Appendix B. The cognitive maps were classified and coded into 19 subthemes. These 
were grouped into five overarching themes that captured the main areas of discussion 
regarding causes and effects of AMR. The themes and subthemes are listed in Table 6.2.  
The following section comprises a qualitative thematic analysis of the interviews. I will 





Table 6.2 Themes and subthemes from the interviews 
THEMES SUBTHEMES 
1. Political and economic 
aspects of AMR 
Pharmaceutical economics and antibiotic development 
The politics of collaboration 
Political prioritisation and funding 
International influences 
2. Antibiotic use and 
resistance in food producing 
animals 
Drivers and impacts of antibiotic use in food producing 
animals 
Industry influence, public pressure and political will  
Transmission of AMR between food animals and humans 
3. Factors that increase the 
risk of infection and 
transmission of AMR in the 
community 
Structural inequities increase vulnerability to infection 
Individual characteristics that increase vulnerability 
Factors driving AMR transmission in the community 
Companion animals 
4. Antibiotic stewardship and 
transmission of AMR in 
health and care settings 
Drivers of antibiotic prescription, and factors affecting 
stewardship 
Emergence and transmission of AMR in health and care 
settings 
Patient use of antibiotics ‘as prescribed’ 
Unintended consequences of antibiotic use in humans 
5. AMR and the environment Sources of antibiotics and resistant bacteria in the 
environment 
Water quality and AMR 
Chemical co-selection of antibiotic resistance 
Wildlife and AMR 
  
6.3 Theme 1: Political and economic aspects of AMR 
Antimicrobial resistance is a complex political, economic and social issue, rather than 
just a biomedical problem that can be addressed with traditional siloed thinking. 
Participants described many high-level factors that contribute to AMR, which I have 





antibiotics, the politics of collaboration, political prioritisation and funding, and 
international influences.  
 Pharmaceutical economics and antibiotic development 
The profit-based economic model of pharmaceutical companies was frequently identified 
as a barrier to the development of new antibiotics, which was seen to reduce our ability 
to cope with antibiotic resistance. This problem was particularly tied to the model of 
market-based antibiotic development, which creates a requirement for profitability: 
“Most antibiotics are subsidised and cheap, you only pay a few 
dollars for them and so from a purely financial point of view from 
a pharmaceutical company it doesn’t make a lot of sense to go to 
considerable effort…developing any new drug is like millions of 
dollars... If they’re not making that commercial pay off, I mean 
that’s just a business decision.” (A19) 
One interviewee linked this situation of a market-based system of antibiotic development 
to wider problematic privatisation of public goods:  
“I don’t think it’s an accident that antibiotics have lived the 
zenith of their existence also during a time when the market and 
our ideological belief in market forces and privatisation of public 
goods has also reached its zenith of time.” (A23) 
Many interviewees emphasised that research and development for any drug is time 
consuming and expensive: it can take 12 years to bring a drug to market, and the cost to 
develop a new drug now exceeds $2.5 billion USD. Approximately one in 6000 products 
will make it all the way through the development pipeline. Research and development 
(R&D) is becoming increasingly expensive, including for antibiotics, because there is 
saturation of drug targets and mechanisms of action: “all the low hanging fruit has been 
picked” (I21). It was felt by some that the cost, difficulty and importance of innovation 
is not recognised enough. Other people talked about how it is much more profitable to 
create drugs for chronic medical conditions, where people take the medicine every day 





Antibiotics are relatively inexpensive to buy, which reduces profit margins for 
pharmaceutical companies. 
 
Several system-level perverse economic incentives were identified. Some interviewees 
talked about how industry promotion of antibiotics partly determines how much 
antibiotics are used. Most antibiotics are given a patent, so the company has a temporary 
monopoly on the drug which it needs to use to recoup investment and maximise returns. 
According to some interviewees, this has resulted in pharmaceutical companies creating 
demand for antibiotics in a variety of settings, including agriculture. However, as AMR 
emerges, it becomes less viable for industry to promote antibiotics. This is partly because 
over-use undermines the longevity of the product, and partly because some 
pharmaceutical companies may feel a sense of global responsibility to prevent AMR from 
worsening, and be concerned about their reputation if they were to push prescribing. 
Another point of interest raised was that drug companies generally educate patients and 
physicians about disease states to promote use of their products (including education on 
correct use). However, there is less incentive for providing education when it is unlikely 
to improve company bottom lines. 
 
A few interviewees also thought that low access to innovative medicines is a problem in 
New Zealand that may affect our ability to deal with antibiotic resistance. Some said 
there is a waiting list of products that have been recommended for funding, with products 
on the waiting list for on average 3.7 years, and sometimes for up to 10 years. However, 
some interviewees cautioned that attributing our growing problem with resistant 
microbes only to shortcomings in supply may be problematic – even with more antibiotic 
discovery, we will be unable to deal with resistance effectively unless we do more to 
conserve the effectiveness of the antibiotics we already have. 
 
 The politics of collaboration 
Collaboration between groups and disciplines was frequently discussed as a contributing 
factor to how well we can address AMR. Many interviewees recognised the complex and 
interconnected nature of AMR, and the need for a One Health approach that integrates 
human, animal and environment disciplines in practice and policy. However, siloed 





“Everyone wants to do good stuff but they don’t want to do it 
with anyone else… We’re all doing individual great stuff and not 
sharing ... Not like the bacteria, we don’t share good ideas. They 
share weapons and advantages, we don’t.”  (CL8) 
The level of collaboration was also thought to affect political will to act on AMR.  
It seemed many groups felt blamed or attacked by others, which stalls progress and 
action. An interviewee discussed how blaming others can lead to strident calls for action: 
“must do this, must do that” (P4), which can be counterproductive and “get people’s 
backs up” (P4), making them less inclined to collaborate and undermining action on 
AMR. These kinds of comments indicate that trust is a central issue. A number of groups 
held the sentiment “if you're not round the table, you're on the menu” (I9). That is, they 
felt if they were excluded from groups addressing AMR, their perspectives would not be 
considered. There was a comment that: 
“There's a feeling almost that it's too much to ask for people to 
stop taking drugs for all their little boo boos, but hey let’s 
pretend the problem is with cattle and farmers, so then we can 
just put it all on the farmers too.” (I9)  
Some interviewees thought that communication and collaboration is starting to improve, 
for example evidenced by the multi-disciplinary AMR working group. Some 
interviewees from human health talked about how since having better communication 
with people from animal health, they now think that much of the antibiotic use in food 
animals may be appropriate, whereas before they just saw the statistics of large volumes 
and thought it must be inappropriate use.  On the other hand, many interviewees thought 
that communication between disciplines has been limited in New Zealand: 
“Quite a big fault, we don’t do it on the health side, animal 
people don’t do it on the animal side; communicating the 





 Political prioritisation and funding 
A lack of political prioritisation of AMR was frequently mentioned as being an issue in 
New Zealand. The AMR Action Plan was widely seen as a good first step, but with 
insufficient people and resources to effectively implement it: 
“The resources to do all that work aren't there. There’s no 
funding. So the AMR group comes up with all these actions, and 
it’s like how are you going to pay for it?” (I7) 
A variety of factors were thought to influence the prioritisation of AMR. These included 
inter-related factors of public pressure, media attention and surveillance infrastructure 
(more infrastructure is likely to result in more surveillance ‘hits’). Several interviewees 
thought competing issues such as Mycoplasma bovis (M. bovis) are being given priority. 
Strength of lobbying from various interest groups was also said to affect political will to 
act. Many interviewees felt a long-standing focus on non-communicable diseases means 
there is less funding available for infectious disease research. Further, ideology and party 
politics were said to have an important effect on how and whether an issue is addressed: 
“Three million dollars was allocated to set up an antibiotic 
resistance surveillance system… but then shortly after, the 
National Party came into power and the money was never 
properly utilized. Because the idea was they were going to set up 
a monitoring system for antibiotic resistance across New 
Zealand. And so that never happened, and that was a decade or 
so ago.” (P6) 
 International influences 
Several interviewees raised the idea that many resistant infections in New Zealand may 
originate overseas, and attributed rising AMR rates in New Zealand to globalisation of 
trade and international travel. AMR was seen as a global issue, with AMR levels in 
resource and regulation poor countries being a particular concern. Some interviewees 
argued that the main AMR threat to New Zealand is likely to originate overseas. Factors 
such as ease of public access to antibiotics, poor sanitation, and low environmental 
standards for manufacturing pharmaceuticals were thought to make Asia and other areas 





thought that fewer regulations on antibiotic use in animals and increased contact between 
humans and animals may also contribute:  
“…Very high-risk, particularly in that one health sphere that we 
sit in, that human/animal/environment interface. There’s some 
amazing data coming out of Asia… sometimes quite scary in 
terms of how much antibiotics they use, unregulated. Sometimes 
they’re using four different antibiotics in pig and poultry feed, 
and all that manure goes straight into the pond where they get 
their fish from, and people get their water from the same sources 
and everything…” (CL11) 
Participants discussed how globalisation means there is a huge amount of travel and 
trade, with international movements of people and animals. Some interviewees thought 
rising rates of medical tourism could increase the risk of resistant infections being 
introduced to New Zealand with returning patients. In the past, contact with healthcare 
settings overseas was the main concern, but now resistance in communities is also high, 
so travellers not exposed to healthcare settings are also at high risk of acquiring resistant 
bacteria. A few participants also considered resistance to be a potential problem in 
imported food from areas where animal agriculture is more intense.  
6.4 Theme 2: Antibiotic use and resistance in food animals 
Many interviewees discussed the use of antibiotics in food producing animals (FPAs), 
and whether this could pose a threat to human health. I will address AMR in FPAs 
separately to companion animals and wildlife, because the way humans interact with 
them and the way they are administered antibiotics is quite different. For example, food 
animals tend to be raised on large scales and high intensity, which drives herd-level 
treatment (often prophylactic) rather than individual treatment. In contrast, pets are 
prescribed antibiotics under similar rationales as humans. Interviewees drew parallels 
between the dilemmas companion animal vets and human doctors have regarding 
individual care versus considering the wider community impacts of antibiotic resistance.  
Therefore, companion animal prescribing is discussed in the next theme. Wildlife are 
mentioned in the environmental section as they were considered by participants to be part 





 Drivers and impacts of antibiotic use in food animals 
Interviewees held a variety of perspectives on the importance of antibiotic use in animal 
agriculture and what, if any, implications this may have for human health. Some felt that 
resistance transmission from food animals to humans is likely to contribute to a 
significant portion of AMR in humans, whilst others thought this transmission is 
practically unlikely, particularly in the New Zealand context.  
Intensity of animal agriculture was seen by many interviewees as a key determinant of 
the level of antibiotic use in food animals. The rationale was that intensification increases 
the number and density of animals, with increased potential for disease transfer, resulting 
in increased prophylactic and overall antibiotic use. However, some disagreed, arguing 
that intensive farming systems allow for increased control of the animals’ environment 
and better management of effluent, reducing spread of disease and therefore reducing the 
need for antibiotics. Many interviewees discussed the importance of disease prevention 
through hygiene, vaccination, nutrition and biosecurity measures. Some interviewees 
thought that industry influence is a driver of the belief that antibiotic use is necessary for 
animal health and welfare, and financial viability. The intensity of animal agriculture 
globally was seen to be driven by a demand for animal products, and in particular 
affordable animal products. One interviewee from human health put it this way:  
“It's funny isn't it, because - I might be wrong - agriculture has 
embraced antibiotics for economic reasons, but it’s going to 
have the opposite effect.” (CL1) 
Many interviewees thought that antibiotic stewardship by farmers and vets would affect 
levels of AMR. Stewardship is here defined as reducing use and increasing 
appropriateness of charting (prescribing), including antibiotic choice, dosing and 
spectrum. Some people felt that vets tend to over-prescribe antibiotics, while others 
thought antibiotic charting by vets is generally well regulated and implemented in New 
Zealand. Those involved in animal agricultural industries said they took care to avoid use 
of antibiotics of human significance. Factors thought to influence stewardship included 
level of education of vets and farmers, competing issues such as M. bovis, cost of testing 
and timeliness of results, and regulations on charting (prescribing).   A perverse incentive 





found in milk, so farmers may be more likely to choose nil-withhold antibiotics for this 
reason, which may not be the best choice for a particular infection (therefore contributing 
to development of AMR). 
Some people on the animal health side felt that the growing debate about use of 
antibiotics in animals could result in re-classification of important antibiotics. This was 
cause for great concern, as they felt they may lose access to some key antibiotics essential 
for animal health and welfare, such as penicillin. This has resulted in stronger guidelines 
by the Veterinary Council to promote antibiotic stewardship and leadership in this area, 
to ensure longevity of antibiotic effectiveness and reduce the risk of losing charting 
rights. 
Interviewees agreed that AMR has serious impacts on animal health and welfare, 
increasing morbidity and mortality. Livestock with persistent infection will often be 
culled, which is hard on farmers economically and emotionally. Many participants 
believed that levels of resistance in FPAs is an important issue abroad, but less so in New 
Zealand. This was attributed by many to our ‘relatively low’ use of antibiotics in 
livestock, resulting from our less intensive pastoral farming systems, and a robust 
regulatory system for veterinary medicines. Most interviewees assumed that antibiotic 
resistance drives use, though some interviewees with expertise in animal health said this 
may not necessarily be a straightforward linear relationship:  
“It doesn’t appear that our use is triggering an increase in 
resistance in animals. So all of the stuff we’re doing (to reduce 
antibiotic use in food animals) is around mitigating AMR in 
people.” (CL11) 
Interviewees with animal expertise were generally more sceptical of animal-human 
transmission. On the other hand, some interviewees felt that agricultural antibiotic use is 
high in New Zealand, and that this could pose a threat to human health. Increasing 
farming intensity, including establishment of feedlots, was seen by some to increase risk 
of AMR. There was a perception that in New Zealand farmers are well aware of consumer 
desire for antibiotic-free agriculture, and respond to that, but that they aren’t so concerned 





“…Farmers understand there is a market desirability for low 
antibiotic use, for clean green, you know… healthy, welfare, all 
that sort of stuff - they've got that picture… I don’t think I've 
heard anyone get wound up about the fact that ‘oh if we use too 
many drugs that can affect human health.’ I haven't heard that. 
It's more about the perception for marketing.”(I9) 
Keeping antibiotic use low was perceived to be a defensive market issue, to maintain 
New Zealand’s premium position. 
 Industry influence, public pressure and political will  
Interviewees discussed how industry influence and public pressure may impact on the 
political will to act on AMR. Some interviewees felt that agricultural lobbying promotes 
the message that antibiotics are essential for animal health, welfare and productivity, thus 
driving antibiotic use in food animals. Some thought that strong agricultural influence is 
a barrier to political action on AMR. On the other hand, the influence of ‘activist types’ 
was seen by some as spreading the ‘incorrect’ idea that antibiotic use in animals is risky 
for human health. I was informed that voluntary actions are being taken by the 
agricultural industry in New Zealand to reduce antibiotic use, as precautionary measures.  
Several interviewees thought that independent research is more likely to find a problem 
with AMR in animals compared with commercial research, which would increase public 
concern about AMR in animals, resulting in pressure on politicians to act to restrict 
antibiotic use in FPAs. A concern was raised that the influence of the agricultural industry 
might restrict research on AMR in food animals, through sending a “clear message that 
this was not an area the industry wanted investigated” (P6). On the other hand, those 
involved in food animal industries and animal health argued that these industries and vets 
are genuinely committed to antibiotic stewardship, and they put forward reasons for why 
antibiotics are used in certain ways. Further, the poultry industry funded studies 





 Transmission of AMR between food animals and humans 
Another subtheme from the interviews was transmission of AMR. Many participants 
described the potential for transfer of AMR from animals to humans, but there was 
variation in how much they thought it happens and how practically important it might be 
for AMR levels in humans. Some participants argued there is little concrete evidence for 
animal to human transmission, but thought it is reasonable to reduce antibiotic use as a 
precaution. Several thought animal to human transmission is unlikely to be a big issue: 
“Obviously we use a lot of antibiotics for drying off cows and 
things like that, but how much that flows on to contributing to 
AMR in humans, I'm far from convinced. We also use lower 
amounts in New Zealand agriculture, so I think to point the 
finger at the agricultural industry would be wrong... But I don't 
think we really have a good handle on it.” (A2) 
Other interviewees thought there could be several plausible pathways of resistance 
transmission between food animals and humans, including direct contact (e.g. farm and 
abattoir workers), and via contamination of the food chain with resistant bacteria. 
Antibiotics and resistant bacteria entering the environment from food animals (via faeces, 
urine and milk) was thought to create an important reservoir of AMR that humans could 
then be exposed to. Use of contaminated manure as fertilizer was also considered to be a 
potential pathway. Some thought the evidence for direct transfer of whole organisms 
from animals to humans is ‘sketchy’ but that horizontal gene transfer from organisms in 
food could play a role. For example, humans may ingest animal bacteria with food, which 
can then mix with our gut flora and pass on resistance genes to human adapted bacteria. 
A number of interviewees also pointed out that resistance can go both ways - and the 
direction of transmission is not always immediately clear even from epidemiological 
studies, which could lead us to make incorrect conclusions about the source species. 
6.5 Theme 3: Factors that increase the risk of infection and 
transmission of AMR in the community 
Many participants described factors that increase people’s risk, or vulnerability to, 
infection - and hence AMR, and discussed drivers of emergence and transmission of 





‘vulnerability’ to mean susceptibility to infection and /or likelihood of being exposed to 
infection. 
 Structural inequities increase vulnerability to infection 
Many interviewees discussed how structural inequities increase the vulnerability of 
certain groups in New Zealand to infection. Socioeconomic deprivation and the 
associated poor nutrition, low housing quality and over-crowding were considered. Some 
argued that New Zealand’s social welfare system is failing to empower people and they 
attributed high levels of inequality in New Zealand to an unfair economic system.  
Several plausible but opposing effects of deprivation on antibiotic prescriptions were 
proposed. Some interviewees thought that physicians may be more likely to use extra 
caution for people they consider especially vulnerable, and therefore prescribe more to 
those groups. Others discussed how those on lower incomes may be more likely to have 
pressures of multiple jobs to juggle, bills to pay and limited sick leave. Combined with 
unaffordability of doctors’ visits, this may mean they delay care-seeking until their illness 
is severe: “unless they really, really, really have to, they won't go (to the doctor)” 
(CO16). On the one hand, accessing healthcare late may reduce the number of antibiotic 
prescriptions, while on the other hand, being more ill due to delayed care seeking could 
increase the likelihood of being prescribed antibiotics. A ‘she’ll be right’ attitude was 
also thought to contribute to late access to health care.  
Many participants identified inequities by ethnicity as an important aspect of the AMR 
system. Considering that Māori and Pasifika groups are disproportionately represented 
in more economically deprived deciles and experience a higher burden of infectious 
disease (see section 2.1), some interviewees thought that antibiotic prescriptions would 
be higher for these vulnerable groups. However others said prescriptions are only slightly 
higher than average for these groups, which may represent unmet need and inadequate 
access to antibiotics. As well as difficulties accessing health care in terms of affordability, 
some interviewees felt that Māori are less likely to be prescribed antibiotics when they 
need them due to underlying institutional and interpersonal racism. As we move towards 
limiting antibiotic use, many interviewees noted that it is important to ensure equitable 





“There are things we've got to be careful about as we try to 
address AMR, one is that as we try to reduce antimicrobial use 
we don't reduce access to legitimate antimicrobial use among 
vulnerable populations, and that is a real risk.” (CL24) 
 Individual characteristics that increase vulnerability to infection 
A common topic of discussion was factors that increase an individual’s likelihood of 
acquiring an infection that may require antibiotics. In addition to groups most affected 
by structural inequities, specific groups who were thought to be at increased risk of 
infection included the very young and the elderly, very sick patients (e.g. 
immunocompromised), and migrants who may have difficulties understanding and 
accessing the New Zealand health system. Some also said that flu vaccination reduces 
the chance of secondary bacterial infection and so can reduce the need for antibiotics. 
Good management of skin health was also seen as crucial: “Managing eczema really well 
is a really important way to prevent skin infections” (CL26).  
  Factors driving AMR transmission in the community 
Interviewees discussed a variety of factors that may increase transmission of resistant 
infections in the community. The amount of antibiotics used in the community was 
considered to be very high, and a key determinant of the spread of AMR. Participants 
considered that the level of antibiotic use in a community will provide selective pressure 
for AMR growth, and is likely to facilitate establishment of resistant infections when they 
are introduced from overseas: 
“Whenever they [resistant bacteria] emerge overseas, sooner or 
later they’ll turn up here. Then what determines how fast the rate 
of exponential growth is in the prevalence of resistance to that 
antibiotic in that organism, is determined I think primarily by 
two things. One is infection control and the other is the level of 
antimicrobial consumption.” (CL22) 
A general agreement was that the more carriers of infection (including resistant 





The same factors that delay care-seeking may also result in people going to work or 
sending their children to school when they are sick, which can drive transmission of 
infection. Additionally, lack of understanding about how infection spreads may lead 
people to think it is harmless to go to work, or see being sick as an opportunity to get 
other errands done. The invisibility of bacteria could make it harder for people to 
understand infection and the importance of hand hygiene, facilitating spread of illness: 
“And I guess the other thing with bacteria is you can’t see it.” (CL1) 
Level of hygiene/sanitation was seen as a very important influence on how easily 
infection spreads in the community. Better sanitation reduces rates of faecal-oral 
transmission, limiting rates of colonisation and spread in the community. Participants felt 
that in New Zealand we have generally good sanitation infrastructure (e.g. water, 
sewerage), but this is much more of an issue in the AMR picture internationally. 
However, several interviewees thought New Zealand still has an embarrassing level of 
poverty for a ‘first world’ country. This is likely to create geographic areas where 
transmission is more common. 
 Companion animals 
Several people talked about companion animals as being part of the AMR picture. I 
discuss companion animals in this section because they are such an integral part of 
humans’ lives, they fit more closely with this section than others. The closeness of contact 
between owners and pets was seen by many interviewees as a risk for transferring 
resistant bacteria (in both directions). Having domesticated animals in hospitals may also 
pose risks in terms of transmission of resistant bacteria. The cost of culturing and 
antibiotic susceptibility testing was described as unaffordable for many owners, which 
could lead vets to have to make a best guess about whether (and which) antibiotics are 
most appropriate: 
“…in clinical practice, you're constrained by finances, it's 
always an onus on the decision around progressing further 
testing etc. So you can do culture and sensitivity which is great, 
we should all be engaging in that …but the reality is, it has to be 





afford to do that’, you don't just not treat the cat, you go ‘well, 
this is my best guess about what we should be doing'.” (P13) 
This could contribute to resistance in animals. Vets can feel a strong pressure to prescribe 
from owners who do not want their animals to suffer. Like in human medicine, there is a 
conflict between focusing on individual health versus considering wider public health 
consequences. Someone also discussed how pets may be exposed to chemicals such as 
herbicides in the neighbourhood environment and track these into the home, which may 
co-select for physiological resistance. Animal shelters were mentioned as potential 
hotspots for AMR spread. Given the number of animals living together in close 
proximity, infection transmission can happen quickly. 
6.6 Theme 4: Antibiotic stewardship and AMR transmission 
in human health and care settings 
This theme is about drivers of antibiotic prescription, stewardship by prescribers of 
antibiotics, and factors affecting whether patients use them as prescribed. There is a sub-
theme about drivers of the emergence and transmission of AMR in health and care 
settings. There is also a section about the impacts of resistance in humans, and other 
unintended consequences that can result from antibiotic use. Overall human antibiotic 
use was thought to be driven by population size and level of antibiotic stewardship. Many 
people thought that AMR in humans is mainly the result of overuse of antibiotics in 
humans (and not very linked to use in animals). Some interviewees felt that New Zealand 
is lagging behind on AMR action, and expressed concern about our high use of antibiotics 
in humans. Most interviewees felt that antibiotic prescription in the community was more 
of a problem than hospital prescribing (I was told that about 95% of total antibiotic 
prescriptions in humans are done primary care in New Zealand) due to volume and the 
fact there is less opportunity to ensure compliance than in hospital. It was thought that 
there is a lot of over-prescribing in this area for things that are minor and trivial.  
 Drivers of antibiotic prescription, and factors affecting 
stewardship 
Many participants talked about the myriad of pressures on GPs to prescribe antibiotics. 





sentiment is: “If I don't leave with an antibiotic the doctor hasn't done the right thing” 
(I20). One person noted that “the average New Zealand child before they go to school 
has 8 courses of antibiotics, which is also a world record” (CL8). Some interviewees 
felt that historically lax stewardship has led to high patient expectation of receiving 
antibiotics. Some referred to threats from patients putting pressure on GPs to prescribe 
antibiotics.  
Many interviewees thought that the cost of GP visits can increase patient expectation of 
antibiotics, and doctor’s feelings of obligation to prescribe. The majority of interviewees 
raised the idea that consumers expect to get something for their money, and this can 
translate to expectation of a prescription. Doctors may feel they need to ‘give value’ by 
prescribing. Further, both doctors and patients know that follow up visits are unlikely 
when cost is an issue. This may make ‘back-pocket’ prescriptions (prescriptions with the 
advice to get antibiotics if a patient gets worse) more commonplace. High patient 
numbers and short consultation times may mean doctors aren’t able to take the time to 
address underlying issues. Giving a pill is a quick fix – “clinicians are treating the 
problem rather than the person” (CO16). Doctors may wish to avoid conflict, and 
especially when under time pressure it may be easier to just write a prescription and avoid 
a complicated interaction.  
Several interviewees discussed how prescribers, particularly GPs, are caught in a ‘grey 
zone’ where they have to balance concern for the health of individual patients with the 
broader public health threat of antibiotic resistance. Doctors are likely to be cognisant of 
wanting to fulfil patient expectations in order to ensure they don’t lose patients from their 
practice, which would result in potential loss of self-esteem and income. They may also 
worry about being subject to a complaint if they don’t. Further, doctors may have the 
attitude that ‘if I don’t, someone else will’. GPs are also under pressure to avoid hospital 
admissions, and effective use of antibiotics in primary care can help achieve that.  
Some interviewees thought that prescribers and patients tend to only think about the 
benefits of antibiotics, and not the possible harmful side effects. They may be seen by 
patients as a ‘miracle drug’ and prescribers may have a ‘prescribe just in case’ attitude. 





also put pressure on GPs, to just give ‘something’. In this way antibiotics may be used as 
placebo drugs to meet patient expectations. 
Hospital prescribing was also discussed. Generally, hospital prescribing in New Zealand 
was thought to be well managed. Hospitals have access to expert advice and the ability 
to monitor patient adherence closely, as well as the opportunity to easily change 
antibiotics as a result of susceptibility testing. It was thought that the level of skill, 
confidence and ability to monitor patients closely in hospital means prescribers are more 
willing to hold off giving antibiotics or to stop antibiotics. Barriers to hospital 
stewardship mentioned by interviewees included an attitude of ‘you don’t tell doctors 
what to do’ and a cultural hierarchy in some cases between various health professionals. 
Fear was a general theme thought to drive over-prescription. People concerned for their 
(or their children’s) health may demand antibiotics. Some interviewees thought there is 
quite a lot of fear amongst the public with regard to infectious diseases, due to social 
media, scaremongering in general media, and strong Ministry messaging around 
infectious diseases such as rheumatic fever and meningitis. Participants understood that 
New Zealand still has high rates of infectious diseases, and doctors may fear a worst case 
scenario if they don’t give antibiotics: 
“I think also fear drives a lot of the expectation from the public 
… But I don’t think that’s just the public. I think there’s a fear in 
prescribers that they’ll miss something important.” (P3)  
Antibiotic choice (narrow spectrum is generally preferable for limiting resistance), dose 
and course duration were discussed under the theme of stewardship. Limited testing 
availability and lack of timely, useful lab results were said to make it harder to ensure the 
correct antibiotic and regime is chosen. Mixed messages around prescribing and use were 
also thought to impair stewardship. For example, previous guidelines recommended 
completing antibiotic courses, while currently there are moves to encourage patients to 
stop taking the doses once they start to feel better – though there was some disagreement 
among participants about whether this is a good idea. Difficulties keeping up to date with 





 Patient use of antibiotics ‘as prescribed’ 
A number of reasons were raised as to why patients may not use antibiotics according to 
the prescribed recommendations, which they thought could have implications for 
antimicrobial resistance. Patients may stop taking antibiotics early because they feel 
better, or if they experience side effects. Physicians may have limited time in a 
consultation to discuss how the medicines should be taken. Lack of patient understanding 
about antibiotic resistance (in some cases linked by participants to socioeconomic 
deprivation) was thought to result in behaviours such as medicine hoarding and sharing. 
Another factor raised was that the level of rapport a physician has with a patient will 
affect how likely they are to follow recommendations. 
It was thought that in some cases, cultural factors may influence how antibiotics are used. 
For example, in some countries, antibiotics do not require a prescription, which may 
mean people travelling to New Zealand from such countries may have elevated 
expectations of receiving antibiotics. An idea was raised that receptiveness of different 
groups to messaging about appropriate antibiotic use is influenced by how much they can 
relate to the content of those messages. For example, if Māori are not represented in 
graphics whilst other ethnicities are, Māori may be more likely to think the 
recommendations don’t apply to them: 
“...because they don’t see themselves there. What a lot of people 
are going to say about those pictures – ‘well they're lovely. But 
that’s not for me’… it's actually pulling them (those designing 
the messages about antibiotics) back into reality. And saying that 
it might be nice for you, the person delivering those nice 
pictures…” (CO16) 
 Emergence and transmission of AMR in health and care 
settings 
Hospitals and rest homes were frequently identified as settings that are likely to be 
‘hotspots’ of AMR. Reasons included high numbers of sick people in close proximity, in 
contexts where antibiotic use is high. Also, patient skin integrity can be compromised 
due to wounds and IVs and so on, further facilitating spread. People in rest homes were 





severity and number of co-morbidities, and skin fragility. The need to make some 
decisions (e.g. use of catheters) based around ease of patient care, versus what is really 
necessary, may contribute. Overall these factors may result in higher antibiotic use and 
therefore levels of AMR in rest homes. The difficulties of not consistently having a 
doctor available on site was thought to reduce timeliness of prescribing, further 
contributing to the problem.  
In hospitals, standards of infection prevention and control (IPC) were commonly 
discussed as a crucial way of preventing transmission of infection (including antibiotic 
resistant bacteria). IPC reduces the likelihood of needing antibiotics and therefore 
reduces AMR emergence, as well as limiting the spread of existing resistant bacteria. The 
distance between patients was seen as an important factor in transmission, and 
overcrowding in ED could be a particular risk. Building design may impact IPC - many 
interviewees talked about how multi-bedded rooms and sharing of toilet facilities in 
hospitals may increase risk of transmission. Staff movements between patients were said 
to increase indirect transmission of microbes between patients if hygiene procedures are 
not well adhered to: 
“My ideal hospital would have a bunch of single rooms each with 
a toilet, and people wouldn’t share… Six bedded rooms in the 
hospital with shared toilet facilities, those provide an 
opportunity for transmission. And healthcare workers can also 
be a vector if they're not washing their hands.” (A2) 
Consistency of screening and isolation procedures was also said to be important. 
Staff commitment to the use of standard precautions, such as personal protective 
equipment, hand hygiene and cleaning standards (including shared patient equipment), 
was seen as very important. Staff buy-in to IPC practices were said to be affected by 
education, and how simplified and streamlined policies and procedures are. Busyness 
may reduce compliance, as can inadequate access to facilities (e.g. for handwashing). 
When under time pressure, systems for IPC may start to break down. The level of rapport 
educators and champions of IPC have with other staff was thought to play an important 





Cleanliness of hospital facilities was frequently discussed as key to reducing 
transmission. Cleaning standards may be affected by level of staff training. Financial 
pressure on hospitals was thought to increase likelihood of contracting cleaning services 
out to the cheapest bidder, which may potentially compromise cleaning standards. Whilst 
cleanliness is important, on the other hand some interviewees discussed the paradox that 
some cleaning chemicals may co-select for antibiotic resistance in bacteria. Therefore, 
the type of cleaning chemicals used may contribute to the problem. One interviewee said 
that older hospitals may have less smooth surfaces and be harder to clean, resulting in 
more use of cleaning chemicals compared to a newer building. 
Environmental factors such as building maintenance and material choices were also 
thought to have an effect on transmission of infection. For example, keeping up with 
maintenance helps to control air flows and pests, while choosing surfaces that are easy 
to clean (such as vinyl flooring, as opposed to carpet) improves hygiene standards. 
With regard to infection transmission in rest homes, some interviewees thought that these 
settings may not have dedicated infection control teams, which would reduce oversight 
of infection prevention and control and may lower hygiene standards. This could result 
in staff inadvertently transferring bugs between patients, especially if rigorous cleaning 
procedures are not followed. The number of patients with incontinence may also increase 
the problem. It is also difficult to put people in isolation when a rest home is their 
residence, as this could be seen almost as punishment. 
This theme and the previous two themes make clear a common idea held by interviewees: 
that having lots of animals (or groups of humans) living in close quarters is a risk factor 
for AMR, particularly when infection control practices are lacking. 
 Unintended consequences of antibiotic use in humans 
Interviewees agreed that in humans, as a general principle, ‘use drives resistance.’ 
Participants discussed a range of impacts of antibiotic resistance. There was consensus 
that the more we use antibiotics (particularly inappropriate use), the more antibiotic 
resistance will impair our ability to prevent and treat infection, which has far reaching 





to prolongation of disease, longer periods in hospital and increased healthcare costs. 
Treatment failure increases risk of patient morbidity and mortality, and is particularly 
dangerous for immunocompromised patients and people undergoing surgery. As first line 
antibiotics of choice become ineffective, this can lead to use of more expensive and less 
desirable antibiotics, which often have worse side effects. In general, resistance was seen 
as an urgent threat to the provision of high-tech healthcare that Western medicine is 
known for. There is a conflict between wanting to optimise individual health by using 
antibiotics, and wanting to preserve antibiotic efficiency and minimise intergenerational 
inequities for this “non-renewable resource” (A23).   
Several interviewees projected increasing isolation requirements as resistant infections 
rise. Whilst it was recognised that isolation is an important tool for reducing transmission, 
some possible harmful effects were also identified. Patients may experience 
psychological harm from social isolation, as well as physical harm due to delays to tests 
and procedures, resulting in poorer outcomes.  
A small number of interviewees mentioned some other possible negative impacts of 
antibiotic use through disruption of an individual’s microbiome. These included potential 
links with Type 2 diabetes, obesity, heart disease, and autoimmune conditions: 
“One of the real issues we have is we don’t see antibiotics as 
doing harm, we only see them as doing good. So we give them 
just in case because what harm could it do? But I think as our 
knowledge of the microbiome starts to develop, and it’s really in 
its infancy, we’ll realise we’re actually causing a lot of the long 
term problems we pick up in all the patients.” (CL8) 
6.7 Theme 5: AMR and the environment 
Several interviewees saw the environment as an important but poorly understand aspect 
of AMR. They discussed this theme in different ways: routes by which antibiotics and 
resistant bacteria may enter the environment, links between AMR and water quality, and 
co-selection of resistance by the range of chemicals humans use in their everyday lives. 
Finally, wildlife are also mentioned in this section because they are commonly 





 Sources of antibiotics and resistant bacteria in the environment 
Interviewees discussed a range of routes through which antibiotics and resistant bacteria 
may enter the environment. Many participants discussed how antibiotics are excreted 
mostly unchanged from humans (and animals), so wastewater from residential, hospital 
and agricultural sources may contain these contaminants. Livestock farming was often 
identified as a key source of antibiotics entering the environment. Some interviewees 
thought we use large volumes of antibiotics in food animals in New Zealand, and 
discussed how animal effluent goes directly onto the fields, and may then enter the 
groundwater or runoff into waterways.  
New Zealand does not currently have waste water treatment systems that can remove 
pharmaceuticals, so they may eventually end up in waterways and the ocean. Incorrect 
disposal of antibiotics may also contribute (e.g. flushing down the toilet):  
“So, the theory is to bring it [unused antibiotics] back to the 
pharmacy and the pharmacy is supposed to work out how it 
needs to be taken care of. But it’s a bit haphazard how that 
happens.” (A12) 
Depending on the robustness of the disposal systems (e.g. incineration is better than 
landfill, lined landfills are safer than leaching), antibiotics may also enter the 
environment through that route. Internationally, discharge of antibiotics from 
pharmaceutical manufacturing factories (especially where environmental standards are 
lacking) into waterways was thought to be a problem, as it results in antibiotic 
concentrations that are sub-lethal to bacteria.  
Overall, increased levels of AMR in environmental bacteria were thought to increase the 
risk of transfer of resistance genes to human pathogens. It was thought that antibiotic 
characteristics such persistence and potency will affect how long antibiotics remain in 
the environment, and the level of selection pressure exerted on environmental bacteria. 
It is possible that crops may be contaminated with antibiotics or resistant bacteria, or they 
may reach drinking water systems. People can also be exposed through activities like 





Some interviewees thought horticultural use of antibiotics could be an issue, especially 
at times when bacterial disease in crops are high. For example, Pseudomonas 
syringae pv. actinidiae (Psa) is a bacteria that affects kiwifruit. It was thought that 
problems such as this might result in more off-label use of antibiotics by growers. 
However, others talked about how New Zealand has auditing and certification processes 
that encourage growers to keep to recommended spray regimes. Evidence of residues 
would also have a significant impact on industry reputation. One interviewee said that 
growers do not view AMR specifically as a threat, but the concept of resistance in general 
(e.g. to insecticides/herbicides) is. 
 Water quality and AMR 
Several interviewees made strong connections between water quality and AMR. Concern 
was expressed about waterways as a reservoir of AMR. Farming practices and entry of 
livestock manure into groundwater and streams was especially concerning. Waterways 
could then be a source of exposure of AMR to other animals and to humans. 
Contamination of water with other chemicals such as herbicides and pesticides was also 
seen to create conditions for resistance emergence. 
An interviewee discussed how as population size and density increases, more 
sophisticated water treatment systems are required. Some participants argued that in 
some areas of New Zealand, urban growth has been unmatched by wastewater treatment 
infrastructure. Release of urban and rural wastewater into our waterways was said to 
severely affect water quality. There were suggestions that the level of contamination of 
rural waterways could be related to intensity of animal agriculture and the amount of 
chemicals used in horticulture.  Complacency about water quality was seen to be an issue: 
“We do have an abundance of water so we're a little bit arrogant 
about not being as good as we can for keeping it clean. Or 
understanding its potential influence on us.” (A14) 
 Chemical co-selection of antibiotic resistance 
Some interviewees discussed how when bacteria are exposed to certain chemicals, this 






“I think the more stressed an organism is, the more likely it is 
going to respond to pressures … the more pressures they're 
under, the more chemicals that are attacking their cell walls, 
coming through their pores, the more vulnerable they are to stuff 
happening to their genome.” (A14) 
I was told that resistance genes are continuously being cycled by horizontal gene transfer, 
but will only accumulate in a population if there is a selective value to that gene. 
Participants discussed a wide variety of chemicals that may co-select for resistance genes, 
ranging from herbicides, pesticides and cleaners to personal care products. For example, 
one interviewee described how herbicides (which are heavily used in both agricultural 
and urban environments) may accelerate the evolution of antibiotic resistance 100,000 
times faster than if there was absence of herbicides. This may be a physiological 
resistance that is temporary, that reverses when the stressor is removed. Some 
interviewees thought that we seem to have become very complacent about commercial 
cleaners, not considering their harmful potential. Over-use of antibacterial products may 
be fed by a fear of germs, which could be a result of both sensible public health 
knowledge, and industry advertising of cleaning products. 
 Wildlife and AMR 
AMR in wildlife was rarely discussed. One participant mentioned that migratory birds 
could possibly carry resistance genes and transmit them to humans. However, this was 
an area of high uncertainty as to whether it is practically likely to pose a significant threat 
to humans. I was unable to interview anyone who was an expert in AMR in wildlife, but 
did gain some understanding of zoo animals and AMR. AMR was not considered to 
currently be a big issue in zoo animals, although there was certainly an awareness of the 
issue. The way zoo animals are administered antibiotics is similar to humans and pets in 
that it is focused on the individual rather than herd treatment. Zoos generally try to avoid 
having to give animals antibiotics, so there is a focus on prevention of infection: 
“…Good diet, good nutrition, good environment, not a stressful 
environment, no overcrowding - all these are things that we can 





Lack of pharmacological studies in wildlife means drugs aren’t very well tested. Also, 
doing diagnostic tests can be difficult on wild animals. Antibiotic choice for zoo animals 
depends on a variety of things, not just sensitivity results, such as which antibiotics are 
most feasible to administer to a wild animal.  
 
6.8 Summary 
This chapter has described the range of stakeholders who took part in interviews, and 
discussed the key themes and subthemes resulting from a thematic analysis of the 
interviews. Five major themes relating to causes and effects of AMR were identified: 
political and economic aspects of AMR; AMR in food producing animals; human 
vulnerability to infection and transmission of infection; antibiotic stewardship and use; 
and AMR and the environment. The next chapter comprises a second results chapter. It 
describes causal loop diagrams that were developed for some of the subthemes discussed 






7 Causal loop diagram analysis 
The previous chapter outlined the results of a targeted thematic analysis exploring 
interviewee’s ideas about the causes and effects of AMR. This chapter begins by 
outlining the reference mode. Then the main focus is describing the causal loop diagrams 
(CLDs), which were synthesised from the interview thematic analysis, the cognitive 
maps, the literature review, and the expert knowledge of the research team. The CLDs 
consist of endogenous variables (involved in the feedback loops of the system (176)), 
and exogenous variables, which are not directly involved in the loops. The exogenous 
variables were described in the thematic analysis, so whilst they are included in the CLDs 
diagrams they are not discussed again here. Larger versions of the CLDs with exogenous 
variables included (where applicable) are available in Appendix F. Please see the separate 
booklet (Appendix G) submitted with the thesis for larger versions of the causal loop 
diagrams in this chapter (with exogenous variables excluded).  
7.1 Reference mode 
The reference mode (see section 5.1) for this study is a qualitative graphical impression 
of how the interviewees believe AMR has changed over time, and their hopes and fears 
for the future. Interviewees all agreed that AMR levels have been increasing over time, 
but had varied ideas about the pattern of growth. Some were hesitant to comment on a 
pattern, citing limited data and changing surveillance methods. Several thought AMR has 
been increasing exponentially, and noted this may not be evident when resistance levels 
are low, but could result in sudden dramatic increases. Some thought the rise was linear, 
and a few thought step wise increases over time were likely. Some interviewees discussed 
the possibility of a sigmoid curve where resistance rises exponentially before levelling 
off. Several interviewees noted that the pattern would be different for different microbes, 
or said that there could be a range of patterns over time. Rising levels of resistance in 
gram negative bacteria was seen as particularly concerning. A few interviewees 
mentioned that the problem of resistance could be slightly over-estimated. 
 
Many interviewees thought the best possible scenario would be to slow the rate of 
increase in AMR. Some hoped that with enough effective action, we may see a plateau 





situation by ‘buying time’; slowing the transmission of AMR for long enough to allow 
development of new effective antibiotics. The optimal situation, some said, would be to 
keep functioning antibiotics for almost every infection. Some worried that we may have 
passed the point of being able to get the problem under control. 
Figure 7.1 displays the ideas above as a graph. The trend until now is simply described 
as increasing, depicted by a linear line, due to the variety of ideas about the exact pattern 
of increase. The worst fear participants had was that AMR would increase exponentially 
from now, as a runaway growth pattern. The most optimistic ‘best case’ scenario that 
was put forward was that we are able to maintain AMR at the current level. 
Figure 7.1 Stakeholder impressions of changes in AMR over time 
People were generally more uncertain about trends of AMR in animals, noting limited 
data. Several interviewees commented that resistance levels in livestock in New Zealand 
is not currently a concern. A few noted that it seems from the data that is available, 






7.2 Causal loop diagrams 
The remainder of this chapter outlines the CLDs for the 13 sub-themes where feedback 
loops were identified. See section 5.2.1 for a reminder of causal loop diagram 
conventions. Reinforcing loops ‘R’ amplify processes, whilst balancing loops ‘B’ 
counteract and oppose change. In cases where the literature review articles included 
feedback loops that were not supported by interview content, these loops are represented 
using green arrows rather than the standard blue. Ideas from the research team about 
connections and loops that were not reflected in the interviews or literature review 
models are indicated in red. Larger versions of the CLDs in this chapter are available in 
the separate booklet (Appendix G). Variables linking feedback loops are retained in the 
simplified CLDs. Exogenous variables (factors identified as being important parts of the 
system, but not involved in feedback loops) are displayed in smaller font and with grey 
arrows in the enlarged CLDs provided in Appendix F. Balancing and reinforcing loops 
are numbered sequentially throughout the CLDs. Dotted lines indicate that the nature of 
the relationship between two variables was contested. 
 Pharmaceutical economics and antibiotic development 
Two reinforcing loops and five balancing loops were constructed for this subtheme 
(Figure 7.2). Balancing loop 1 (B1 ‘basic use of antibiotics for treatment’) is based on a 
feedback loop from Homer et al. (2000). This balancing loop communicates the idea that 
if there are greater numbers of sick and hospitalised people, the resulting physician visits 
are likely to result in antibiotic prescriptions. This antibiotic use feeds back to reduce the 
numbers of sick and hospitalised people. Although the interviews did not specifically 
raise this idea, links between antibiotic use and individual health were made by 
interviewees. 
B2 (‘AMR limits antibiotic use’) illustrates interviewee’s ideas that the more antibiotics 
are used, the more resistance becomes a problem. This undermines antibiotic 
effectiveness in the long term and therefore limits the amount of antibiotic sales, which 
may slow resistance. Many interviewees felt the limitation resistance imposes on 
antibiotic sales is a strong disincentive for pharmaceutical companies, who need to make 






Figure 7.2 CLD: Factors affecting development of new antibiotics. See Appendix F for 
full diagram with exogenous variables. 
Homer et al. (2000) suggested an alternative (reinforcing) feedback loop to describe the 
relationship between antibiotic use and resistance. This loop (R1 ‘antibiotic resistance-
use spiral’) is shown in green, and posits that use of antibiotics leads to resistance, which 
undermines the effectiveness of antibiotic treatment. This may increase the number of 
sick and hospitalised people, resulting in more physician visits and more antibiotics being 
prescribed, which further perpetuates resistance. This concept was not supported by the 
interviews. 
B3 (‘R&D response’) is based on a feedback loop in the model from Homer et al. (2000), 
which was supported by the interviews. Participants described how as antibiotics become 
less effective, this results in the need for more research into antibiotic development, 
increasing the funding given to this venture. With a delay (my addition from the 





antibiotics, improving the effectiveness of antibiotic treatment. The delay mark is 
justified by many participants’ discussions of R&D as a lengthy process.  
B4 (‘cost containment response’) is also based on a loop identified by Homer et al. 
(2000), which was not supported by the interviews. It posits that as resistance increases 
and more research and funding is put into developing new antibiotics, the cost of 
antibiotics may increase. This would likely reduce the willingness of third parties to pay 
for antibiotics, resulting in a reduction in the amount of antibiotics consumed and 
therefore reducing the problem of antibiotic resistance. Note that as the polarities of these 
links were not specified in Homer et al. (2000), I had to make assumptions about the 
likely polarity. 
B5 (‘resisting change’) is based on the idea that restricting access to antibiotics would 
help preserve antibiotic efficacy; a disinvestment that could result in future health gain. 
However, it was thought that moves to restrict access to certain antibiotics would upset 
clinicians and industry groups, who would then increase pressure on regulatory agencies 
to allow access, countering the initial policy. 
 
R2 (‘antibiotic restrictions reduce antibiotic development’) is a feedback loop that may 
counter B3. Antibiotic resistance naturally leads to policies aiming to reduce use, which 
diminishes the profitability of developing new antibiotics. Reduced profit potential was 
thought to be a key factor limiting R&D, resulting in low development of new antibiotics. 
This may further drive policies to limit antibiotic use as part of a reinforcing feedback 
loop. Conversely, if new antibiotics are developed this could possibly result in a relaxing 
of antibiotic stewardship (which would lead to more resistance, but would also increase 
the attractiveness of developing antibiotics). Many saw this coupling between antibiotic 
sales and pharmaceutical profits as problematic. 
 
 The politics of collaboration  
Four reinforcing loops and one balancing loop were identified within the theme of 
collaboration (Figure 7.3). R3 (‘competitive thinking’) illustrates that some interviewees 





wanting to take the credit for good ideas alone. This undermines sharing of ideas and 
strategies for combatting AMR, creating a vicious cycle that undermines collaboration.  
 
The set of reinforcing loops on the right side of Figure 7.3 (R4 - R6: ‘trust and blame’, 
‘learning from each other’, and ‘effective action motivates working together’) illustrate 
how good communication and sharing of ideas increases effective action and 
understanding between sectors. This reduces blaming of other groups and can become a 
virtuous cycle that promotes further collaboration (R4).   
 
 
R6 was identified by the research team as a possible feedback loop by which more 
effective action leads increased willingness to collaborate, which leads to more effective 
action. 
 
A balancing loop (B6 ‘spinning wheels’) was also identified in this collaboration sub-
theme. It was pointed out that more collaboration generally calls for more people to be 
at meetings, which can make gaining consensus difficult. In the case of the AMR action 
group, the fact that many people are involved inconsistently was thought to slow 






consensus building and therefore the speed of work. This can make people frustrated with 
the process and less inclined to want to collaborate.  
 Political prioritisation and funding 
In Figure 7.4 below, R7 is slightly amended from the ‘surveillance/funding spiral’ in 
Homer et al. (2000). The interviews supported the idea that the more funding of AMR 
research and action there is, the more surveillance infrastructure there is likely to be. This 
will increase the amount of surveillance hits, garnering more media attention. Hopefully 
this would increase political prioritisation of the issue and lead to more spending on AMR 
in a reinforcing loop.  However, some interviewees noted that unfortunately, surveillance 
doesn’t always lead to action. 
 
The connected reinforcing loop (R8 ‘public pressure affects political priorities’) displays 
interviewees ideas that increased media attention on the topic of AMR will increase 
public understanding of the issue, leading to increased pressure on the government to act. 
However, this media coverage needed to be accurate and informative, not 
‘scaremongering’.  






 International influences 
Figure 7.5 shows a feedback loop that was identified within the theme of international 
influences. Interviewees discussed how high levels of AMR overseas were said to 
increase travellers’ likelihood of exposure, and the risk of returning home carrying 
resistant microbes. Given the global nature of AMR, as AMR levels rise there may be 
increased attempts at global governance and international restriction of antibiotic use 
(R9: ‘international context’). This would further limit pharmaceutical profitability of 
making antibiotics, which could have the unfortunate effect of further driving production 
to countries were labour is cheap and environmental regulations are low. This would act 
to reinforce the cycle by further raising levels of AMR in these countries. 
 Drivers and impacts of antibiotic use in food producing animals 
The CLD describing influences on animal antibiotic use (Figure 7.6) consists of two 
reinforcing loops and five balancing loops. Both balancing and reinforcing loops link to 
the perception that antibiotic use in FPAs improves productivity. Links between 
antibiotic use and resistance in animals are shown using dotted lines because although 
Figure 7.5 CLD: International influences on AMR. See Appendix F for full diagram 





most interviewees agreed that more use leads to higher levels of AMR, some thought we 
haven’t seen clear evidence to support this.  
Figure 7.6 CLD: Influences on antibiotic use in food animals. See Appendix F for full 
diagram with exogenous variables. 
R10 ‘desirability of antibiotics’ may be acting to encourage increased antibiotic use in 
food animals. Several interviewees talked about how antibiotic use in food animals can 
improve productivity (and therefore farmer profit margins), for example by encouraging 
faster weight gain (R10). This was thought to increase the assumption that antibiotics 
improve economic efficiency. This leads to more antibiotic use, which increases 
productivity, and so on, in a reinforcing feedback loop. A connected reinforcing loop 
(R11 ‘antibiotics reduce sickness’) is that antibiotic use helps reduce animal sickness and 
mortality, improving productivity and further driving R10.  
R12 (‘trying higher doses’) is based on a feedback identified by Henriksson et al. (2018). 
They postulated that in the aquaculture sector, increasing levels of AMR results in use of 
more antibiotics, in an attempt to over-come reduced microbe sensitivity (e.g. trying 
higher doses). This was not a concept discussed by the interviewees. 
Some interviewees talked about how if less antibiotics are used, animals will be at higher 
risk of infection, which would result in more antibiotic use (B7 ‘underuse creates greater 
need for antibiotics’). An example discussed was that if less antibiotics are used for 





therapeutic levels of antibiotics, which could result in greater use overall. One person did 
note that this increase in therapeutic antibiotic use following restrictions in sub 
therapeutic use can be a temporary effect. 
Another balancing loop (B8) could be described as ‘antibiotic resistance deters antibiotic 
use’. Use of antibiotics drives higher levels of antibiotic resistance in food producing 
animals, which will reduce effectiveness of antibiotic treatment, meaning food animals 
have higher levels of morbidity and mortality. This will reduce farm productivity and 
weaken the assumption that antibiotics improve economic efficiency, likely resulting in 
less antibiotic use. However, it may take some time for resistance levels for a particular 
antibiotic to reduce after removal of that antibiotic (delay mark). Some interviewees 
thought that once resistance levels are higher than a certain unknown ‘tipping point’, 
restriction of a particular antibiotic may have little effect. Another delay area could be in 
discovering that reduced antibiotic effectiveness is due to resistance (as opposed to, for 
example, simply using the wrong antibiotic for an infection). These delays may make B8 
relatively weak and slow to have an effect.  
A set of balancing loops (B9, B10, B11) relate to the perception of risk to human health, 
resulting in less use of antibiotics in FPAs. B9 ‘consumer demand’ shows how 
international regulations and market demand for low antibiotic use will affect the way 
farmers perceive the profitability of using antibiotic and further drive down antibiotic 
sales and use. Also, if farmers use antibiotics their products will be seen as less desirable, 
reducing their profit and therefore meaning they have less money available to buy 
antibiotics anyway.  
 
B10 ‘market access’ shows how perception of risk by health authorities and consumer 
demand for antibiotic free animal products can also drive such actions (e.g. the EU 
banned the use of antibiotics as growth promoters in 2006, and moves to restrict 
metaphylaxis and prophylactic use are currently underway). Countries are also beginning 
to put standards in place for antibiotic use in animal products they import.  
 
B11 ‘risk perception and action’ is similar to the ‘media and public pressure’ feedback 





raised about possible transmission of resistance from animals to humans, there is a 
growing perception of risk to human health (amongst researchers, policy 
makers/regulators, and the public). Increased media attention will also facilitate public 
awareness and concern. Public concern about the issue is likely to increase pressure on 
those in power to act, resulting in moves to reduce antibiotic use in FPAs (e.g. stronger 
regulation, better stewardship).  
 
 Industry influence, public pressure and political will  
The CLD below (Figure 7.7) connects to the CLD in Figure 7.6, as the loops involved 
will drive the amount of antibiotics used in animals. Two reinforcing loops and one 
balancing loop were synthesised from the theme of how industry influence and public 
pressure may affect political will to act on antibiotic use in animal agriculture. 
 
Figure 7.7 CLD: Industry and public influences on AMR action. See Appendix F for full 
diagram with exogenous variables. 
R13 shows a reinforcing loop where ‘power reinforces power’. One interviewee noted 
that power of the agricultural industry can result in punishment of people who speak out, 
which may result in less people being willing to raise concerns or delve into the topic. 
This further reinforces the perception that farming practices are unquestionable, as well 






R14 ‘public pressure and political will’ reflects the perception among participants that 
more political will to act would increase the amount of independent research and funding 
related to determining AMR prevalence in animals. Levels of public concern are likely 
to rise or fall directly in response to reported resistance levels and in turn influence 
political action. However, a balancing loop (B12: ‘industry counteracts pressure’) 
reflects a view that public pressure may cause industry to downplay the seriousness of 
the problem, reducing public concern and weakening the pressure to act. 
 Structural inequities increase vulnerability to infection 
Five reinforcing loops were synthesised relating to structural inequities that drive 
vulnerability to infection (Figure 7.8).  
 
Figure 7.8 CLD: Structural inequities drive vulnerability to infection. See Appendix F for 
combined CLDs for Figures 7.8, 7.9 and 7.11, with exogenous variables. 
Many interviewees expressed concern about how socioeconomic deprivation could play 
an important role in vulnerability to infection, via multiple pathways: via poor nutrition 





Deprivation was also thought to limit educational opportunities, possibly resulting in less 
understanding of how infection spreads (R19). Lack of knowledge combined with other 
barriers resulting from living circumstances were thought to have an effect on hygiene 
and infection prevention practices, putting people at increased risk of infection. This 
affects both the amount of bacteria in the community environment and how easily they 
are transmitted between people. All these loops (R15 - R19) can increase susceptibility 
to infection. Overall this means people are more likely to be unwell and unable to work 
(as well as being likely to receive antibiotics, which could drive resistance). This further 
limits income and increases deprivation, reinforcing the above vicious cycles.  
 Factors driving AMR transmission in the community 
Several participants talked about the idea that ‘prevalence drives incidence’ (R20 in 
Figure 7.9). A higher prevalence of infectious disease means that more people will be at 
risk of exposure, and therefore vulnerable to infection, driving incidence of disease. 
Higher incidence reinforces higher prevalence. This is similar to the ‘contagion spiral’ 









 Drivers of antibiotic prescription and factors affecting 
stewardship 
R21 (‘setting a precedent’) in Figure 7.10 illustrates the perception by some interviewees 
that historical over-prescription of antibiotics has created a situation where it is difficult 
to back-track. Over-prescription in the past, including as placebos, has normalised 
antibiotics for both patients and clinicians. This leads to patients having high expectations 
of receiving antibiotics for even minor ailments, increasing pressure on clinicians to 
prescribe and reinforcing over-prescription. 
Antibiotics were also described as powerful anxiolytics (R22) – both the prescriber and 
the patient tends to feel better when they are prescribed. Normalising of antibiotic use 
may feed patient anxiety about infection, putting further pressure on clinicians to 
prescribe antibiotics.  
 Emergence and transmission in health and care settings 
Two reinforcing loops (R23 and R24 in Figure 7.11) were identified that can make 
patients more vulnerable to infection in a hospital setting. Interviewees referred to the 
risk of increased numbers of potentially pathogenic microbes in hospital. Longer stays in 
hospital increase the length of time patients are exposed to potential infection, making 
them likely to become more ill and have to stay longer (R24). Several interviewees 
posited that the longer someone stays in hospital, the more likely it is that the integrity 
of their skin barrier will be compromised due to more IVs, catheters, bed sores etc. The 
skin is a key barrier to infection, and the importance of managing skin health to reduce 





the risk of acquiring and transmitting bugs was commonly mentioned. Compromised skin 
integrity increases likelihood of infection, which may further prolong a stay in hospital 
(R23).  
Figure 7.11 CLD: Factors increasing vulnerability to infection in the hospital context 
 Unintended consequences of antibiotic use in humans 
Two interconnected balancing loops were constructed from participants’ ideas about the 
unintended effects of antibiotic use (Figure 7.12).  
Figure 7.12 CLD: Unintended effects of antibiotic use leads to action 
Some participants considered that in New Zealand we may be relatively protected from 
antibiotic resistance initially, due to vaccination coverage, generally good sanitation and 
good nutrition as compared to developing countries. It was thought that this could create 





problem. However, as B13 (‘action is limited until problem is serious’) in the above CLD 
shows, as resistant infections rise and AMR starts to have more obvious and direct 
impacts on more people, this will likely increase public and political concern about the 
problem, resulting in policies and personal actions to reduce inappropriate use of 
antibiotics. This may stall the progress of resistance. 
A small number of interviewees also talked about other possible unintended 
consequences of antibiotic use. This was said to be an area of increasing research and 
concern. Antibiotic use can disrupt the normal microbiome, and this damage to our 
natural flora may be a pathway in the aetiology of conditions such as Type 2 diabetes, 
obesity, heart disease and autoimmune problems (B14). There is also the more well-
known contribution to Clostridium difficile (this bacteria can cause gastro-intestinal 
issues following use of antibiotics). B14 (‘knowledge about harm reduces antibiotic use’) 
suggests that as these kinds of problems become more prevalent and better researched 
(which may take some time, as indicated by the delay mark in the diagram), physicians 
and patients may start to shift away from the perception that antibiotics only do good, 
resulting in less unnecessary use. 
 Water quality and AMR 
As displayed in Figure 7.13, two balancing loops were synthesised for this theme. B15 
(‘complacency about fresh water’) represents interviewees’ discussion around how New 
Zealand has historically been considered as ‘pure, clean and green’ with pristine water. 
One interviewee said that for a long time we haven’t had to worry about water quality, 
possibly leading to public and political complacency about preserving water quality. 
Lack of pro-activeness has led to the current culminating issues around fresh water, and 
several interviewees were particularly concerned about impacts of agricultural 
intensification on water quality. As the problem worsens and awareness and concern 
rises, action is more likely. However, there could be a time delay before we see physical 
improvements in water quality resulting from action. Contamination here includes 
antibiotics, bacteria, and herbicides, pesticides, and other chemicals. B16 (‘poor water 





political concern increases, action may include better water treatment to help balance 
water quality.  
Figure 7.13 CLD: Water quality and AMR. See Appendix F for full diagram with 
exogenous variables. 
 Chemical co-selection of antibiotic resistance 
A reinforcing loop was constructed under this theme of co-selection (Figure 7.14). 
Figure 7.14 CLD: Superbugs. See Appendix F for full diagram with exogenous variables. 
 Fear of germs may lead to over-use of antibacterial agents, which paradoxically may 
increase levels of resistance. As AMR increases, fears of ‘superbugs’ and germs in 






 Overall model 
Figure 7.15 below shows the integration of the previously discussed feedback loops, 
omitting exogenous variables for clarity. Please see the attached A3 page (with the 
separate booklet, Appendix G) for a larger version. ‘Level of AMR in humans’ was a 
central variable with many interconnections, so this is emphasised in the overall model. 
 
Figure 7.15 Overall model  
7.3 Summary 
This chapter began by describing the varied perceptions participants had about how AMR 
has changed over time, and their hopes and fears for the future. It then described causal 
loop diagrams that were associated with sub-themes. Next, for the final chapter of this 
thesis, I discuss what the results of this participatory system dynamics approach mean in 







This thesis has aimed to answer the questions:  
1. What are the relationships between different aspects of human, animal, 
and environmental health in relation to antimicrobial resistance, within 
the New Zealand cultural and political context, as perceived by a variety 
of stakeholders?  
2. What are the feedback loops that are driving trends in AMR over time in 
New Zealand? 
In this chapter I summarise the main findings of my research and discuss their meaning, 
contextualise the results within the wider literature to highlight what this study adds, 
discuss strengths and limitations of my study, consider implications of the study, and 
make recommendations for future research.  
8.1 Summary and interpretation of the principal findings 
 Stakeholder perspectives on One Health aspects of AMR  
My findings show that experts in New Zealand have diverse (and sometimes 
contradictory) perspectives on the causes and effects of antibiotic resistance in New 
Zealand. Whilst all agreed that levels of resistance in humans and animals has been 
increasing over time, participants disagreed about the exact pattern of AMR growth. This 
may indicate there is a real need for better surveillance data to more comprehensively 
establish how resistance levels for different organisms are changing, which could help 
different stakeholders come to a shared view of the severity of the problem.  
Collectively, interviewees saw AMR as a highly complex issue, with many human, 
animal and environmental factors involved and inter-linked. However, there was no 
overall consensus between interviewees as to which factors are the most important 
drivers of AMR in New Zealand. The range of causes and effects of AMR discussed by 
interviewees corresponded well with my background reading, representing a wide range 
of knowledge and opinions. Disagreement about the relative importance of each sector 
may stall action in reducing antibiotic use, which will be required to reduce AMR.  The 





AMR is set within a broader political and economic context, with strong international 
influences. There are many complex barriers to the development of new antibiotics which 
can be linked to the profit-dependent nature of pharmaceutical companies. However, 
simply creating new antibiotics is unlikely to solve the AMR problem. Collaboration 
between different disciplines appears to be improving in New Zealand, but blaming and 
limited trust between some groups is still an issue. AMR is not high on the political 
agenda, which limits our ability to address it. Resistance is an international issue, and 
many of the resistant infections in New Zealand are likely to have originated overseas.  
The impact of antibiotic use in food producing animals on human health was an area 
of disagreement in the interviews, a debate which is also reflected in the literature (8, 61, 
65). Some interviewees saw antibiotic use in food animals as a threat to human health, 
while others were more sceptical of such links. There was also some disagreement around 
whether greater intensity of agriculture drives more use of antibiotics. Some interviewees 
expressed concern about the strength of the agricultural lobby in New Zealand, while 
others stressed the precautionary approach livestock industries take to antibiotic use. The 
issue of antibiotic use in food producing animals was clearly linked with wider political 
and economic contexts, through discussion of underlying economic motives for antibiotic 
use, political influence of industry, and discussion of the intensification of agriculture. 
Factors that increase the risk of infection and transmission of AMR in the community 
was another overarching theme. Vulnerability of different groups to AMR was frequently 
linked to wider structural inequities in New Zealand, including issues of poverty and 
income inequity, housing quality, and inequities in access to healthcare by income and 
ethnicity. This theme was therefore also linked more broadly to the political and 
economic context of New Zealand. Individual level characteristics were also considered. 
The closeness of interactions between humans and companion animals may also increase 
risk of AMR transmission.  
Levels of antibiotic stewardship and transmission of AMR in health and care 
settings was another important theme. General Practitioners face many pressures to 
prescribe antibiotics, and community prescribing was widely seen as the main contributor 





more regulated. On the other hand, the risk of AMR and transmission of resistance was 
thought to be higher in health-care compared to community settings. As well as AMR, 
other possible unintended consequences of antibiotic use were also contemplated.  
Several interviewees saw the environment as an important but poorly understood aspect 
of AMR. Concern was raised about antibiotics and resistant bacteria entering the 
environment from farm runoff and urban wastewater. The environment theme was 
therefore closely linked to the issue of antibiotic use in food animals.  Higher background 
levels of AMR in the environment was thought to increase the risk of transfer of resistant 
genes to pathogens of human significance. Water quality was seen as a very relevant 
aspect of the AMR picture. Co-selection of AMR as a result of use of chemicals such as 
commercial cleaners, herbicides and pesticides is another potentially significant 
contributor to AMR.  
This research has highlighted some of the complexities, disagreements and contradictions 
surrounding the issue of AMR, confirming that AMR is a classic complex problem with 
multiple stakeholders and policy resistance. Participatory system dynamics modelling is 
likely to be a particularly helpful approach in such situations. 
The political and economic environment was a cross-cutting idea across many of the 
above themes. This demonstrates that antimicrobial resistance is inextricably linked to 
high-level drivers beyond the control of most individuals. A small number of 
interviewees specifically linked AMR to capitalism, particularly in relation to the profit-
driven model of antibiotic development and the macroeconomic incentives for antibiotic 
use in agriculture. Many of the structural inequities in income, housing and healthcare 
access discussed by interviewees are also a result of similar macroeconomic policies. 
Therefore, it is likely that addressing antimicrobial resistance will require a shift in our 
political approach to economic policy, to prioritise reducing inequities and create a 
system for antibiotic development that is based on the social good of antibiotics. Many 
of the current strategies for addressing AMR tend to focus on technological and 
biomedical solutions, but greater acknowledgement of AMR as a fundamentally socio-





 Feedback loops driving trends in AMR in New Zealand 
Causal loop diagrams were developed based on the thematic analysis, cognitive maps, 
literature review, and supervisory expertise. CLDs were developed for 13 of the 19 
interlinked subthemes identified in the thematic analysis, summarised below. 
1. Five balancing loops and two reinforcing loops were synthesised for the subtheme 
‘pharmaceutical economics and antibiotic development’. Most of the 
balancing loops represent barriers to development of new antibiotics, which could 
indicate progress in this area is unlikely under current profit-driven models of 
drug development.  
 
2. Under the theme of ‘politics of collaboration’, four reinforcing loops and one 
balancing loop emerged. Improved collaboration would result in these reinforcing 
loops operating as ‘virtuous cycles’, fostering improved communication and 
reducing blame between sectors. However, the balancing loop also needs to be 
managed in the process of encouraging collaboration, to ensure that the large 
numbers of people at meetings don’t result in reduced communication and 
increased frustration.  
 
3. The ‘political prioritisation and funding’ subtheme illustrated how increased 
political prioritisation of AMR, such as spending on surveillance, may give a 
clearer picture of the problem, garnering media attention and pushing further 
political action. This was also thought to be mediated through public 
understanding of the issue and pressure on politicians. 
 
4. The single loop synthesised for the ‘international influences’ subtheme 
illustrated the fact that AMR is a global issue. It shows that policies to restrict 
antibiotic use may paradoxically push more antibiotic production into resource 
and regulation-poor countries, further contributing to the global level of AMR. 
 
5. The ‘drivers and impacts of antibiotic use in food animals’ subtheme 
comprised three reinforcing loops and five balancing loops. As established in the 





it is reasonable to postulate that the reinforcing loops may currently be 
dominating: despite the side effects of antibiotics and increasing restriction of 
their use, their perceived positive impact on productivity may currently be 
stronger. However, as resistance levels increase and concern about transmission 
to humans reaches a tipping point, the reinforcing loops may become less 
dominant; antibiotic use may not seem so desirable or profitable, which could 
result in less use and help contain AMR. 
 
6. The CLD for the ‘industry influence, public pressure and political will’ 
subtheme comprised two reinforcing loops and one balancing loop. The loop 
showing that ‘power reinforces power’ could bolster the influence of the 
agricultural industry, which some interviewees thought would result in less 
political will to restrict antibiotic use in animals. It was thought that independent 
research on AMR in animals would be more likely to find a problem than 
commercially funded research, resulting in public pressure on politicians to act. 
However, there was also the idea that industry would react to downplay the 
seriousness of the problem and placate public fears.  
 
7. The CLD for the ‘structural inequities increase vulnerability to infection’ 
subtheme consists of five reinforcing loops and no balancing loops. Poor 
nutrition, chronic illness, poor housing quality, overcrowding and reduced 
education as a result of deprivation were all thought to play a role in increasing 
the vulnerability of some groups to AMR. Vicious cycles of deprivation may be 
key area to target in the fight against AMR.  
 
8. The one reinforcing loop for the ‘factors driving AMR transmission in the 
community’ subtheme illustrates the epidemiological observation that 
prevalence drives incidence. 
 
9. The two reinforcing loops under ‘drivers of antibiotic prescription and factors 
affecting stewardship’ show how normalising prescription of antibiotics may 
have set a precedent, resulting in high patient expectations of antibiotics that are 
difficult to shift. This is further driven by use of antibiotics to relieve anxiety 






10. Two reinforcing loops under the ‘emergence and transmission of AMR in 
health and care settings’ subtheme display how longer hospital stays may 
increase risk of acquiring resistant infections. 
 
11. On the other hand, the two balancing loops under ‘unintended consequences of 
antibiotics use in humans’ illustrate how rising numbers of resistant infections, 
as well as learning about other harmful effects of antibiotics, may help to reduce 
antibiotic use. 
 
12. The ‘water quality and AMR’ CLD consisted of two balancing loops, that 
illustrated how as water contamination reaches a critical threshold, public and 
political complacency about water quality may be over-come. Action on water 
quality may help reduce the co-selection of antimicrobial resistance in the 
environment. 
 
13. In a related subtheme ‘chemical co-selection of antibiotic resistance’, the 
reinforcing loop illustrates that a fear of germs and overuse of antibacterial 
products may paradoxically worsen our problem with antimicrobial resistance. 
 
While these 13 CLDs were presented separately for clarity and simplicity, they are 
inextricably intertwined. Therefore, I have also brought them together into an overall 
model of the AMR system in New Zealand to demonstrate this, and show where the 
connection points are (Figure 7.15). A total of 41 loops were synthesised for the overall 
model. Of these, 25 were reinforcing loops and 16 were balancing loops. Eight of the 
loops were based on feedbacks identified in the literature review (39, 80, 88-90, 113). 
Four of these loops also appeared in the interviews, and four did not. The remaining 33 
feedback loops were entirely new.  
8.2 What this study contributes 
This is the first time internationally that participatory system dynamics modelling has 
been used to create an integrated model of the human, animal and environmental aspects 





the AMR system in diagram form that incorporates two or more of human, animal, and 
environmental domains, and none have done so comprehensively.  It also appears to be 
the first such study explicitly underpinned by One Health and EcoHealth principles. 
These frameworks have proved useful in guiding this research, and have aligned well 
with my values of equity, sustainability, and stakeholder inclusion in the research 
process.  
Despite increasing calls for One Health approaches to the issue of AMR, there is a 
significant gap in implementing this in an integrative way. The studies that met the 
inclusion criteria for the literature review tended to focus on modelling the transmission 
of resistance from animals to humans, with varying levels of complexity. Some included 
a small reference to the environment as a transmission pathway or reservoir of AMR, but 
this dimension was generally under-investigated. Most included some reference to 
policy, but specific policy recommendations arising from the models were not often 
discussed. 
The literature review showed that system dynamics modelling holds potential for 
integrated modelling of AMR, but as yet this potential has not been fully realised. There 
was a clearly identified need for a model that included all three domains, with an explicit 
focus on feedback loops. Previous modelling efforts which used system dynamics 
methods were often limited by a lack of focus on feedbacks, and in some cases did not 
use standard SD conventions. Participatory modelling had also been under-utilised in 
these modelling efforts, despite recent recognition that this may be a useful way to 
operationalise systems thinking and One Health (20, 30). This research has sought to 
address the above mentioned gaps in AMR modelling.  
In total, the previous models included eight feedback loops related to AMR. The 
interviews supported four of these, and also identified 33 new feedbacks for further 
exploration. Loops from the literature review that were supported by the interviews 
included the R&D response of pharmaceutical companies (39) and the surveillance and 
funding spiral (39). The ‘risk perception and action’ loop was similar to the ‘media and 
public pressure loop from Grohn et al. (2017), and the ‘prevalence drives incidence’ loop 





the findings of this thesis were: ‘resistance use spiral’ (39), ‘resistance leads to more 
antibiotic use’ (113), ‘basic use of AB for treatment’ (39) and ‘cost containment 
response’ (39). It is possible that further discussion with the participants in this research 
would support the incorporation of these feedbacks into the New Zealand model of AMR. 
The large number of novel feedback loops found in this study clearly highlights the 
complexity of AMR. This also appears to be the first time that balancing complexity and 
outlining stakeholder understandings has been the explicit purpose of an AMR model.  
In keeping with previous research (18, 85), my findings clearly show that AMR is far 
more than just a biological issue; there are wider social, political and economic forces 
involved. The many feedback loops and interconnections between factors illustrate that 
changes in one variable can have far reaching effects. This study has demonstrated that 
there is more to AMR than specific microbe level or population transmission models. 
Although microbe-level and population transmission models are important for learning 
about AMR, this project has shown that wider economic and political drivers, which have 
largely been absent from previous research, are important for effective AMR policy. 
One Health and EcoHealth frameworks have been useful in guiding my research, and 
have aligned well with my values of equity, sustainability, and stakeholder inclusion in 
the research process. Participatory system dynamics has proved to be a useful method for 
operationalising the integrative and systems thinking principles demanded by One Health 
and EcoHealth. The underlying principles EcoHealth were very useful for guiding my 
research process.  
8.3 Evaluation of the study 
 Strengths 
This study had a number of strengths. It has been novel in terms of approach – as far as 
we know, it is the first participatory system dynamics study on AMR that explores all 
three of the human, animal and environmental dimensions of the problem. It also appears 





The study involved a large number of interviews, allowing for a diverse range of 
perspectives on AMR to be included, successfully representing all parts of the sampling 
frame except for one (community environment). Interviews generate rich descriptions of 
processes, causal understandings and feedback (191). By the end of the interviews I 
reached information saturation in terms of suggested causes and effects of AMR in New 
Zealand. Face-to-face interviewing may improve rapport building and facilitate more 
detailed answers compared with telephone interviews (192, 195). Face-to-face interviews 
enabled me to undertake cognitive mapping during the interviews.  
Building rapport between the researcher and participants is important, especially for 
building trust in a participatory modelling process. Participants expressed their 
appreciation of the efforts to involve them in the project, including travelling around the 
country to meet with them face to face. I believe that meeting them in person made it 
easier to develop a connection and for interviewees to talk more openly. Giving 
participants the option to check their transcripts and cognitive maps was designed to also 
build trust in the research (although some commented they did not enjoy reading their 
transcripts). Most of those who replied regarding the cognitive maps commented that 
they were happy with the content, or that while they did not necessarily understand the 
conventions of such diagrams, the points they raised seemed to be covered. Almost all 
interviewees expressed interest in being kept informed of possible future work involving 
a group workshop. 
In this research I have addressed some of the issues of validity and quality I identified in 
previous modelling studies. I explicitly aimed to enhance the transparency and usefulness 
of the process and model by: having a clearly articulated purpose; using an a-priori 
participant sampling strategy to identify participants; shaping interview questions to 
elicit a model that is fit for purpose; ensuring the interview transcripts and cognitive maps 
reflected the mental models of participants (by double checking of interview transcripts, 
participant approval of transcripts and cognitive maps); striving for balance between 
complexity and simplicity to ensure the model is both comprehensive and 
understandable; and ensuring correct use of SD modelling language and identification of 





The focus on feedback loops in this preliminary SD model is a strength of this study. 
Although we have not yet tested the comprehensibility of the CLDs with participants, 
there is existing evidence that causal loop diagrams can allow quick and effective 
communication about the key components and interactions in a system (196). This 
provides some justification for a claim that the model will be useful for decision-makers, 
once refined and validated. This preliminary model has provided a transparent, 
comprehensive starting point for future work to build on. 
In addition, I am unaware of any other study that has sought the views of such an 
extensive group of stakeholders on the matter of AMR in New Zealand, building on the 
work of Majowicz et al. to identify non-traditional stakeholders (90). This research has 
built the foundation for a participatory system dynamics process by carrying out the 
critical initial steps of stakeholder assessment and preliminary interviews (166). 
Interactive group participation will be the next stage of the process.  
 Limitations 
The gaps in representation are one limitation of this research. Finding representation in 
the community aspect of the framework was the most difficult. A representative from a 
community organisation advocating on AMR from an environmental perspective could 
not be found within the timeframe of this thesis. This may indicate that AMR is not yet 
on the agenda of the environmental NGO community in New Zealand. The perspective 
of a patient experience of antibiotic resistance was also missing from this study. No 
patient advocate groups exist for this issue in New Zealand. Further work is needed to 
identify participants to fill these gaps in the next steps of the research. Although the 
sample of interviewees was weighed towards some aspects of the sampling frame, this 
was justified by the number of different types of roles within that particular box, or by a 
lack of suitable participants in other areas. 
It is also worth considering that the One Health/EcoHealth basis of the model relies on 
there being a demonstrated transmission of AMR between animals, the environment, and 
humans. Although many interviewees and much of the AMR literature take this One 
Health concept as a given, there are also some areas of contestation, especially regarding 





readings and in the interviews. There was consensus between the interviews and the 
literature that the environment is generally considered to be likely to be important for 
AMR, but this was a relatively under-studied and less discussed area. Overall the strength 
of the evidence seems to point to transmission between all three domains being possible, 
but the relative importance of each is less clear. Consolidating the evidence base around 
this and building consensus among stakeholders and policymakers will be crucial. 
The simplicity of causal loop diagrams, while having some benefits acknowledged 
above, can potentially result in incorrect interpretations (196). Causal loop diagrams do 
not distinguish between information links and rate-to-level links, which can result in the 
situation where “the traditional definitions of positive and negative links fail in a wide 
variety of cases” (196 p. 160). That is, the presumption that a positive sign indicates 
variables moving in the same direction and minus sign indicates variables moving in the 
opposite direction may not always be applied correctly. Richardson (1986) suggests this 
definition of a positive influence in a CLD: “A has a positive influence on B if an increase 
(decrease) in A results in a value of B which is greater (less) than it would have been had 
A not changed” (p161). Future work on this model will ensure that postulated causal 
links are in keeping with this more robust definition. Conversion of the CLDs into 
quantitative models would also help eliminate this problem.  
In addition, the reference mode and the CLDs currently reflect only the knowledge of 
participants (although these stakeholders do represent much of New Zealand’s AMR 
expertise), and a small amount of input from the literature. The model needs to be 
validated more thoroughly by: testing the model with the participants themselves; 
triangulation with the wider AMR literature; and simulation modelling, which will allow 
the testing of the causal theory against real world data and trends.  
It is worth noting that the loop structures are likely to change when the model is 
quantified in the future. Part of this will be due to changing the model format to represent 
stock and flow structure, which is not possible in the CLDs. This may require some 
explanation to stakeholders, as the loops may seem to no longer align directly with their 






The size and complexity of my model may be another limitation. Ghaffarzadegan et al. 
(2011) make a case for the usefulness of small system dynamics models in the public 
policy process. They suggest that the optimal model size is a few significant stocks and 
a maximum of seven or eight major feedback loops (156), in order to allow capturing of 
key insights while maintaining ease of understanding and communication of the issues. 
By these criteria, the overall model resulting from my research may be too large to aid 
policy making at this stage. However, the separate CLDs fit within the optimal size 
suggested by Ghaffarzadegan et al. (2011). Further work could address this issue by 
simplifying the overall model further. 
8.4 Implications for policy and future research 
This study indicates that addressing AMR will require consideration of intertwined issues 
such as poverty and inequity, farming practices, water quality, widespread use of 
chemicals, impacts of globalisation, and the ‘for-profit’ model of medicine development. 
This research suggests that an ongoing lack of consensus between various experts on 
AMR is likely to hinder effective policy-making. While diverse viewpoints are legitimate 
and contribute meaning, and there may be no ‘one truth’ about AMR, further work to 
foster collaboration and understanding between disciplines will be beneficial. Many 
participants highlighted the need for such an approach. Greater understanding of alternate 
perspectives may increase trust and reduce blame by ensuring all parties feel heard. The 
participatory system dynamics model developed in this study helps by bringing diverse 
understandings together into a shared causal theory of the system. 
The large number of reinforcing loops identified could be interpreted as highlighting the 
difficulties that may be encountered as policies to reduce AMR are tried. With further 
work it is possible that some of these may be identified as key leverage points to target 
and avoid policy resistance. In order for this model to be applicable to policy and practice 
beyond speculation, the next steps in the participatory system dynamics modelling 
process (as shown in Figure 5.2) need to be carried out. However, based on these 
qualitative results, I make some tentative initial policy recommendations here. Several of 
these are structural level recommendations, which contrast with the current focus of 






1. There is an urgent need to improve integrated surveillance of AMR in humans, 
animals and the environment in New Zealand, to establish a clearer baseline 
understanding of the nature of the problem and the shape of change in AMR over 
time. This will be critical to understanding the combination of feedback processes 
driving AMR trends, and therefore for designing effective policy interventions. 
 
2. Policies to improve equity in income, housing and access to primary healthcare 
are likely to have beneficial effects on levels of infection, antibiotic prescribing 
and use behaviours, and AMR. Of course, such policies will also have many other 
co-benefits outside of addressing antimicrobial resistance. 
 
3. Continue to foster collaboration between different disciplines as part of a One 
Health approach. There were several interlinked feedback loops synthesised on 
this topic. These feedbacks suggest a need to find balance in terms of participation 
– participation needs to be broad and inclusive, whilst operationalised in a way 
that makes people feel progress is being made at a reasonable pace. 
 
4. Explore alternative modes of funding for antibiotic development, as private for-
profit models appear to be ineffective in this case.  
 
5. Further develop the evidence base for non-antibiotic chemicals, including 
agrichemicals and personal care and cleaning products, in accelerating resistance 
evolution. Where evidence for these links exist (e.g. for the herbicide glyphosate 
(197-199)), we should take precautionary action to restrict use of these 
substances. Herbicides such as glyphosate have also come under scrutiny for 
other negative human and environmental health impacts (200). 
 
6. Many interviewees agreed that there is a need to improve New Zealand’s water 
quality. This might be done partly through considering farming practices and 






My aim was to construct CLDs specifically for New Zealand, but it is possible that the 
generalised nature of many of the feedbacks means they may be applicable to other 
countries. However, it is likely that the relative strength of the feedbacks would vary.  
This study raises a number of recommendations for future research. Further work is 
planned to progress the model built in this thesis. An initial step would include more in-
depth triangulation with the wider AMR literature, to confirm that the postulated links in 
the model are supported by evidence. Another important step would involve workshops 
with groups of stakeholders - ideally those initially involved in this project, in addition 
to addressing the gaps in representation. This would be used to assess the level of 
consensus on the model, and likely result in some additions and refinements. Building 
confidence in the usefulness of the model is an important aspect of validating the model.  
Group model building that involves stakeholders meeting in person would be beneficial 
for refining and improving the validity of the model, as well as building a shared sense 
of ownership and commitment to using the results of the modelling to achieve policy 
change. Eventually the refined qualitative model would need to be converted to a 
quantitative system dynamics model, to allow for more formal validity testing of the 
model and understanding of which feedbacks are dominating the AMR system in New 
Zealand. Development of a quantitative model would also enable simulation to test the 
effects of possible policy interventions. 
Similar studies could be carried out in other countries to see how similar models are 
between different settings. In addition, the environment domain of AMR could be an area 
to explore further. Several participants in this study saw this as a potentially important, 
but under-studied, area. This could include testing for antibiotic levels and presence of 
resistant bacteria in different settings. More assessment of the links between antibiotic 
resistance in food animals and humans may also be beneficial, to help address some of 
the conflicting views on this topic. Many interviewees thought New Zealand’s context (a 
developed country with a large number of farm animals) makes us well placed to conduct 
such research. More One Health research on antibiotic resistance is essential, and further 






The lack of integration of knowledge about what drives AMR currently means that there 
are conflicting views between important stakeholder groups about the most effective 
policies to address it.  Despite the absence of a comprehensive evidence base, urgent 
policy decisions are needed to address AMR. ‘Systems thinking’, which takes a holistic 
approach to understanding complex systems and how the component parts interact, is 
particularly useful in informing policy decisions in such situations. This research has 
taken the first steps in a participatory system dynamics process to improve understanding 
of the AMR system in New Zealand, including human health, animal health, and 
environmental components, by drawing on a wide variety of stakeholder perspectives to 
develop a causal model. 
Maintaining and enhancing the health and wellbeing of all New Zealanders will require 
a system-wide response to the threat of antibiotic resistant infections, in order to prevent 
disease caused by already existing resistant bacteria, and by preventing the rise and 
establishment of others. This project has contributed to a system understanding of the 
problem of AMR in New Zealand, using a novel approach. It provides a preliminary 
model to aid understanding of the complexity of relationships between human, animal 
and environmental health in relation to AMR in New Zealand. A large number of novel 
potential feedbacks were discovered through this model building process. The 
participatory dynamic causal theory provides a basis on which further quantitative 
modelling and testing work can be done, with the ultimate goal of guiding policy and 
action plans on AMR. Having a well-constructed model to inform policy decisions will 
improve the quality of those decisions and their effectiveness in limiting the impact of 
antimicrobial resistance.  
This novel approach to addressing AMR holds potential for improving the quality of 
policy-making, acknowledging Einstein’s famous statement that “we can’t solve 
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Appendix B: Cognitive mapping conventions and examples 





Each variable (concept/construct) is worded in such a way that it could have a ‘level’ – 
it could move up or down. For example, ‘economic incentives to develop new antibiotics’ 
is a variable that could have greater or lesser amounts. Arrows are drawn between 
variables to show how they are thought to be causally related. Polarities indicate the type 
of relationship.  A "+" sign next to an arrow means that if the variable at the start of the 
arrow changes up or down, the variable at the end of the arrow will move in the same 
way (more leads to more, or less leads to less). A "-" sign indicates that if the variable at 
the start of the arrow moves in one direction, the variable at the end will move in the 
opposite direction (more leads to less, less leads to more). For example, if the causal 
variable goes up, the dependent variable will go down. Some variables are set up as 
opposing poles, separated by an ellipse. The "..." is read as "rather than". For example, 
the profitability of making drugs for chronic conditions "rather than" antibiotics. Delay 
marks (II) on arrows indicate a time delay between the causal and dependent variable. 
For the example above, 'duration medications are taken' is a variable written in such a 
way that it could go up or down. If it is a long term medication (for chronic conditions), 
it is likely to be more profitable for the pharmaceutical company (plus sign, same 
direction) compared to making antibiotics which are short term medications. If the 
profitability of making drugs for chronic conditions is higher than for antibiotics, then 





direction). In cases where variables link in such a way to form loops, these are called 
feedback loops.  





































Appendix C: Participant information sheet 
 
 
Understanding antimicrobial resistance in New Zealand 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Thank you for considering the request to take part in this study. Please read this 
information sheet carefully before deciding whether or not to participate.   
 
This project is being undertaken for Sarah Mitchell’s Master of Public Health (MPH). 
Antimicrobial resistance (AMR) is a growing global public health crisis that threatens 
our ability to effectively treat and prevent infectious diseases. We aim to bring together 
human, animal and environmental health perspectives about AMR in New Zealand. This 
will be done using systems thinking, which is a way of looking at complex problems that 
seeks to understand the interconnections between elements of a system. Interviews with 
stakeholders will be used to build up a combined picture of the system to inform AMR 
policy in New Zealand.  
 
We are looking for expert stakeholders in some part of the dimensions above (human, 
animal and environmental health), from policy, clinical practice, science, community and 
industry, who are in a position to understand and/or influence policy. You have been 
invited to participate as you are a member of one or more of these groups.  
 
Should you agree to take part in this project, you will be asked to take part in one 
interview with the research student. Sarah will travel to interview participants.  
 
During the interview, mapping diagrams will also be drawn to picture the relationships 
between cause and effect during the interviews. This map will be checked with you to 
confirm it accurately reflects your perspective. The interview process is likely to take 
between 60-90 minutes. The interview will be audio-recorded and transcribed and, 
following the interview, your transcript and map will be provided to you so that you can 
check its accuracy. The stakeholder interviews will be analysed to draw out a collective 
understanding of AMR in New Zealand. The research student, her supervisors, and a 
research assistant will have access to the interview information.  
 
The data collected will be securely stored in such a way that only the research student 
and her supervisors will be able to gain access to it. Data obtained as a result of the 
research will be retained for 5 years in secure storage. Audio-recordings will be 





results of the project may be published and will be available in the University of Otago 
Library (Dunedin, New Zealand). Results of the study will also be made available to you 
as a stakeholder report at the end of the project.  
 
The group of New Zealand experts in AMR is small, and maintaining anonymity in this 
project will be difficult. We will take care when using quotes to minimise the likelihood 
of attribution to individuals. You will be given the option of being acknowledged as an 
individual contributor, having your organisation listed as a contributor, or neither, in any 
written reporting.  
 
Your participation is voluntary, and you can end the interview at any time, without any 
disadvantage to yourself. We will provide you with a transcript of your interview for your 
review and confirmation of accuracy. You can withdraw any information given up to the 
point of transcript confirmation.  
 
If you have any questions about our project, either now or in the future, please feel free 
to contact: 
Dr Alex Macmillan 
Department of Preventive and Social Medicine 
University Telephone Number: +64 3 479 7196      
Email: alex.macmillan@otago.ac.nz  
 
This study has been approved by the Department stated above. However, if you have any 
concerns about the ethical conduct of the research you may contact the University of 
Otago Human Ethics Committee through the Human Ethics Committee Administrator 
(ph +643 479 8256 or email gary.witte@otago.ac.nz). Any issues you raise will be 












Appendix D: Consent form 
 
 
UNDERSTANDING ANTIMICROBIAL RESISTANCE IN 
NEW ZEALAND 
CONSENT FORM FOR PARTICIPANTS 
 
 
I have read the Information Sheet concerning this project and understand what it is about.  
All my questions have been answered to my satisfaction.  I understand that I am free to 
request further information at any stage. 
I know that: 
1. My participation in the project is entirely voluntary; 
 
2. I am free to withdraw from the project up until the time I confirm my interview 
transcription, without any disadvantage; 
 
3. Audio recordings will be destroyed after the interview has been transcribed and 
then reviewed by me, but any raw data on which the results of the project depend 
will be retained in secure storage for five years; 
 
4.  This project involves an open-questioning technique. The general line of 
questioning includes the causes and effects of the AMR problem and suggested 
policy recommendations.  The precise questions have not been determined in 
advance, but will depend on the way the interview develops. If the line of questioning 
develops in such a way that I feel hesitant or uncomfortable I may decline to answer 
any question(s) and/or may withdraw from the project without any disadvantage of 
any kind. 
 
5. I understand that it may be difficult to maintain my anonymity because of the 
nature of my expertise, and that any quotes used will not be attributed to individuals.  
 
6. The results of the project may be published and will be available in the University 
of Otago Library (Dunedin, New Zealand) but every attempt will be made to 



















.............................................................................   ............................... 
                     
       (Signature of participant)     (Date) 
 
............................................................................. 
       (Printed Name) 
 
 
8. I, as the participant (please tick one or two boxes as appropriate):  
 
 
a) agree to my name being listed as a contributor in the research,  
 
b) agree to have my organisation listed in the research, 
 
c) would rather neither my name nor organisation is listed 
 
 













Appendix E: Semi-structured interview outline 
Semi-structured Interview Sheet 
 
Introduction 
Thank you very much for agreeing to participate in this project. I am interested in finding 
out about your perspective on antimicrobial resistance in New Zealand. I would like to 
know what you think are the main problems contributing to AMR and their effects. I am 
interested in all aspects of AMR, including human, animal and environmental health.   I 
will be focusing on the relationships between variables you identify in this interview and 
will be mapping these out as we talk. At the end of the interview I will show you this 
map and make sure it accurately reflects what you have told me.  I will be audio recording 
this interview and transcribing it so I can analyse it more thoroughly.  This information 
will help me to build up a shared picture of how stakeholders think about AMR in New 
Zealand.  I will share the results of this project with you in a report.    
 
Warm up  
Before I get into the main questions about the causes and effects of AMR, I’d just like to 
ask a few more general questions about yourself and what you think about AMR. 
 
- Could you start by telling me a bit about what your role is in your organisation 
and how it relates to AMR? I believe you also have roles in… 
- What was it about this project that interests you/made you want to take part? 
- What do you think has been happening to AMR over time? (E.g. has it been 
increasing in a linear way? Exponentially?) 
- How do you see it progressing in the future if we continue business as usual? 
What would be the best case scenario if everyone got their act together? 
- Going back to what you think is happening to AMR, what factors do you believe 




- What do you think are the main 









- What do you think causes that/is 
underlying that? 
- What effect/consequences does 
that have? 




- Short term and long term effects 
- How long does it take… 
- Who, what, when, how…. Actors, 
resources, information flow, 
imperatives 
- Who carries the cost of these 
effects? Does anyone benefit? 
- How might this affect equity? 
 
 
Here is the map I’ve been drawing during the interview. Does this accurately reflect what 
you think? Are there any changes or additions you’d like to make? Can you explain this 
part in more detail for me? 
 
Wrap up 
Is there anything else you think I need to know? 
 




Thank you very much for your time! Once I have transcribed this interview and tidied up 
this map I will email them to you for a final check and approval. 
 
My supervisors are hoping to continue work on this AMR project beyond my Masters. 
This may involve some workshops with groups of stakeholders. Would you be willing to 
be contacted by them for further involvement in the future? 
 
 
Appendix F: Enlarged CLDs, with exogenous variables shown 
 
























































Appendix G: Enlarged CLDs (without exogenous variables) 
 
For submission with Sarah Mitchell’s Master of Public Health thesis: 
An integrated approach to antimicrobial resistance in New Zealand 
 
This Appendix provides larger versions of the causal loop diagrams in Chapter 7  

















































































Figure 7.15 Overall model 
 
